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Abstract 
 
The currently approved integrase strand transfer inhibitors (INSTIs), raltegravir (RAL) and 
elvitegravir (EVG) effectively halt HIV-1 replication but their use is limited by their low 
genetic resistance barrier and cross resistance. For instance, integrase amino acids N155 and 
Q148 represent genetic pathways selected by both drugs and are associated with considerable 
cross resistance to both RAL and EVG. Dolutegravir (DTG) is a second generation drug 
manufactured to exhibit a more robust resistance profile than RAL and EVG, and retains 
activity against RAL and EVG resistant isolates. Most research on drug resistance patterns 
have been carried out with emphasis on HIV-1 subtype B and inadequately assessed in HIV-1 
subtype C. Thus, the aim of this study was to establish the drug resistance mutation profiles 
of HIV-1 subtype C primary virus isolates that evolve/emerge under selective pressure of the 
INSTIs RAL, EVG and DTG, and evaluate their impact on strand transfer. In vitro selection 
experiments were carried out using six primary virus isolates (three wild-type, FV, and three 
reverse transcriptase drug resistant, MR, viruses) grown in peripheral blood mononuclear 
cells in the presence of increasing concentrations of RAL, EVG and DTG, and monitored to 
beyond virus break-through. Viral RNA was extracted from various time points and the pol 
region was RT-PCR amplified and sequenced using conventional Sanger-based sequencing 
and next generation sequencing (Illumina MiSeq).  HIV-1 subtype C FV6 wild-type and 
mutant recombinant integrase (generated by site-directed mutagenesis) were expressed, 
purified and used in strand transfer assays and surface plasmon resonance (SPR) experiments 
to establish the binding affinities of IN-DNA. Wild-type FV primary viruses were 
successfully grown in the presence of increasing concentrations of RAL, EVG and DTG, up 
to 266 nM, 66 nM and 32 nM, respectively. Drug resistant MR viruses were successfully 
grown in the presence of increasing concentrations of RAL, EVG and DTG, up to 266 nM, 
16 nM and 8 nM, respectively. Sequence analysis on both platforms revealed the presence of 
the previously described drug resistance mutations T66IK, E92Q, F121Y, Q148R, N155H 
and R263K in some viruses, and additionally H114L was detected. RAL was observed to 
select for substitutions Q148R and N155H/H114L in isolates FV6 and MR69, respectively. 
EVG selected F121Y, T66I/R263K, T66K and T66I in FV3, FV6, MR69, MR81, and MR89, 
respectively. DTG selected substitutions E92Q and M50I in FV3 and MR81, respectively. In 
silico data exhibited changes in hydrophilicity, hydrophobicity and side chain changes as well 
as changes in polarity, and all substitutions displayed acceptable minimisation energies and 
V 
 
distances between the atoms. Seven IN mutants were expressed and purified, and thereafter 
tested for efficiency in strand transfer. All mutant FV6T66I, FV6E92Q, FV6H114L, FV6F121Y, 
FV6Q148R, FV6N155H and FV6R263K IN enzymes demonstrated an overall loss in strand transfer 
capacity of 37.1%, 21.5%, 66.1%, 63.2%, 60.2%, 30.5% and 3.4%, respectively. This is the 
first report on loss of strand transfer activity associated with H114L. The loss in strand 
transfer capacity in all the mutants was not reflected by their overall binding affinities to 
donor DNA, as determined by surface plasmon resonance, likely attributed to the role of 
different residues associated with DNA and drug binding in the IN quaternary structure. In 
conclusion, this is the first report describing IN drug selection experiments using primary 
HIV-1 subtype C isolates, and a detailed genotypic and biochemical characterisation  of the 
associated mutations.   
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CHAPTER 1: INTRODUCTION 
 
 
1.1. Introduction to HIV and AIDS 
1.1.1. History and global epidemiology of HIV 
Acquired immunodeficiency syndrome (AIDS) was first diagnosed in 1981, in a homosexual 
male patient that exhibited an immune deficiency state associated with opportunistic 
microbial infections (Gottlieb et al., 1981). It was in subsequent years that AIDS was 
confirmed to be caused by a retrovirus, then designated Lymphadenopathy associated virus 
(LAV) (Barre-Sinoussi et al., 1983) and later designated Human T-lymphotropic Virus Type 
(HTLV)-III (Popovic et al., 1984). In 1986 HTLV-III was appropriately named Human 
Immunodeficiency Virus Type-1 (HIV-1), since infection of humans with the pathogen 
resulted in immune depletion (Coffin et al., 1986). Although the initial diagnosis of HIV-1 
was in the early 1980’s; the virus has been sequenced from samples dating back to the 1970s, 
1960s and 1950s (Froland et al., 1970; Jonassen et al., 1997; Zhu et al., 1998; Keele et al., 
2006). For instance, clinical samples from Norwegian patients dated 1971 and 1976 have 
exhibited infection with HIV-1 group O (William et al; 1983; Froland et al., 1988; Jonassen 
et al., 1997). Other historical HIV-1 tissue samples include ZR59 obtained in 1959 and DR60 
obtained in 1960 (Zhu et al., 1998; Keele et al., 2006). The ZR59 tissue sample is the oldest 
known HIV-1 sample, obtained from an African male patient in The Democratic Republic of 
Congo (DRC) (Zhu et al., 1998; Keele et al., 2006). Sequence analysis of the HIV-1 sample 
ZR59 has shown close phylogenetic relation with Simian Immunodeficiency Virus (SIV) 
strains isolated from primate Pan Troglodytes troglodytes (Keele et al., 2006). The HIV-1 
sample DR60 is a lymph node biopsy which was preserved in paraffin wax since 1960 
(Worobey et al., 2008). Sequence analysis of DR60 has shown a 12% nucleotide variation 
with respect to ZR59, a disparity caused by introduction of mutations. This mutational 
variation suggests that HIV-1 infections were present in humans for a considerable period 
before 1960 (Worobey et al., 2008).  This notion is supported by statistical sequence analysis 
that estimated the existence of HIV-1 as early as 1915-1941; with the year 1931 being an 
optimum estimate for a common ancestor of HIV-1 group M (Korber et al., 2000).  
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Since its discovery in the early 1980’s, HIV- infection has been reported in every country of 
the world. The Joint United Nations Programme on HIV/AIDS (UNAIDS) report on the 
global AIDS epidemic, has estimated that approximately 35.3 million (32.2 million – 37.2 
million) people were living with HIV by the end of 2013. Of these 2.1 million (1.9 – 2.4 
million) were new HIV infections which included 240 000 (210 000 – 280 000) newly HIV-
infected children (UNAIDS World AIDS Day Report - Fact sheet, 2014). HIV/AIDS 
associated global mortality rates for year 2013 were estimated at 1.5 million (1.4 million -1.7 
million) worldwide compared to 1.6 million (1.4 million – 1.9 million) from year 2012, of 
which approximately 1.4 million (1.2 million – 1.7 million) adults and approximately 
210 000 (190 000 – 250 000) being children under the age of 15 years (UNAIDS, 2013; 
UNAIDS World AIDS Day Report - Fact sheet, 2014). 
 
Sub-Saharan Africa remains the most burdened region by the global pandemic with an 
HIV/AIDS prevalence of approximately 24.7 million people by end of 2013, of which 58% 
are women. In the same year (2013) new HIV infections in sub-Saharan Africa were 
estimated to be 1.5 million (1.3 million – 1.6 million), and approximately 1.1 million (1 
million – 1.3 million) died from HIV/AIDS related deaths (UNAIDS World AIDS Day 
Report - Fact sheet, 2014). South Africa remains the country with the highest HIV-1 
prevalence in the world with an estimated 6.1 million living with HIV (UNAIDS, 2013; 
Avert, accessed 2015-01-26). Statistics South Africa reported a 93% increase in HIV/AIDS 
associated deaths between 1997 and 2006, and a mortality rate of 82% between 2006 and 
2010 (Statistics South Africa, 2013). 
 
1.1.2. Nomenclature and phylogeny of HIV-1 
HIV can be classified into two types, HIV-1 and HIV-2; both are from the Retroviridae 
family, Orthoretrovirinae subfamily and the genus Lentivirus (The International Committee 
on Taxonomy of Viruses, Virology Division-IUMS 
http://ictvonline.org/virusTaxonomy.asp?taxnode_id=20124900 accessed 2014 January 6).  
 
Both AIDS viruses originated from primate SIV, and were obtained by humans through 
multiple zoonotic transmissions in West and Central Africa (Hemelaar, 2012) (Figure 1.1). 
HIV-1 and HIV-2 represent two distinct lineages of primate reservoir (Hirsch et al., 1989; 
3 
 
Huet et al., 1990; Gao et al., 1992; Sharp et al., 1995). For instance, HIV-2 originates from 
SIV-infected sooty mangabeys (Cercobus atys) and this was identified through genome 
sequence relations of HIV-2 with SIVsmm; a virus common in sooty mangabey (Hirsch et 
al., 1989; Huet et al., 1990; Gao et al., 1992; Sharp et al., 1995). HIV-2 has been divided into 
seven non-recombinant groups A, B, C, D, E, F and G; and one circulating recombinant form 
(CRF) HIV2_CRF01_AB (HIV sequence database: 
http://www.hiv.lanl.gov/content/sequence/HelpDocs/subtypes.html, accessed 7 January 
2015). 
 
The HIV-1 primate reservoir was identified to be the chimpanzee subspecies P.t. troglodytes 
and P.t. schweinfurthii common in central and eastern Africa. These primates were identified 
to be natural carriers of SIVcpz and SIVcpz-ant; viruses closely related to HIV-1 (Peeters et 
al., 1989; Peeters et al., 1992; Janssens et al., 1994; Van Haesevelde et al., 1996). The close 
genome sequence relationship between SIVcpz strains from primates in Cameroon with HIV-
1 add to existing evidence of cross species infections from primates as a source of HIV-1 into 
humans (Simon et al., 1998; Gao et al., 1999; Corbet et al., 2000; Sharp et al., 2001).  
The currently circulating HIV-1 has shown extensive diversity and phylogenetic analysis has 
divided the virus into four distinct groups, namely; HIV-1 groups M (major), N (non M non 
O), O (outlier) and group P. HIV-1 group P was isolated in 2009 from a Cameroonian woman 
residing in France, and genome sequence analysis proved the primate reservoir to be gorillas 
due to the close sequence relations with SIVgor (HIV sequence database: 
http://www.hiv.lanl.gov/content/sequence/HelpDocs/subtypes.html, accessed 7 January 2014; 
Plantier et al., 2009). HIV-1 group M represents the predominant group, and consist of 9  
non-recombinant subtypes A (with sub-subtypes A1, A2), B, C, D, and F (with sub-subtypes 
F1, F2), G, H, J and K (HIV sequence database: 
http://www.hiv.lanl.gov/content/sequence/HelpDocs/subtypes.html, accessed 7 January 
2014). Moreover, HIV-1 group M currently consists of 72 circulating recombinant forms 
(CRFs),  unique recombinant forms (URFs)  and second generation recombinants (SGRs) 
(Robertson et al., 2000; Hemelaar et al., 2006; McCutchan, 2006; Carr et al., 2010; 
Hemelaar, 2012; Lau et al., 2013; HIV sequence database:  
http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html, accessed 19 January 2015).  
CRFs are known to emerge as a result of recombination between two HIV subtypes in 
epidemiologically unlinked individuals, and are responsible for major epidemics. For 
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instance, recombination between HIV-1 subtypes B and F has produced CRF_12BF; the 
designated number 12 is a representation of the order in which the CRF was reported. URFs 
are formed during recombination of three or more epidemiologically unlinked HIV-1 
subtypes (Lau and Wong, 2013).  
 
1.1.3. Transmission of HIV-1 
Transmission routes of HIV-1 include sexual, parenteral and vertical transmission; and each 
route is associated with a distinctive risk of infection (Royce et al., 1997; Galvin and Cohen, 
2004). The sexual route is the main method of transmission and includes male-to-female, 
female-to-male, male-to-male and fellatio; and is associated with a 1 in 200 to 1 in 2000, 1 in 
700 to 1 in 3000, 1 in 10 to 1 in 1600 and 1 in 10 to 1 in 1600 risk of infection, respectively 
(Royce et al., 1997; Galvin and Cohen, 2004). Parenteral transmission includes transfusion of 
HIV-1 infected blood and needle stick injuries. Vertical transmission is from mother-to-child 
and has less than a 1 in 10 risk of infection during azidothymidine (AZT) treatment, and a 1 
in 4 risk of infection when individuals are untreated (Royce et al., 1997; Galvin and Cohen, 
2004).  
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Figure 1.1: Phylogenetic tree illustration of genome sequence relationships of HIV-1 and HIV-2 in humans 
with respect to primate SIV. This figure was obtained from Tebit and Arts, (2011). 
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1.1.4. Geographical distribution of HIV 
The HIV pandemic is immensely diverse in geographical distribution, with regional 
epidemics harbouring varying subsets in global diversity. For instance, HIV-2 has primarily 
been confined to Africa while HIV-1 exhibits a global prevalence. HIV-2 group A has been 
identified mainly in Angola and Mozambique, with isolated incidences in Brazil and India 
(Faria et al., 2012). HIV-2 group B has been in identified in isolated cases in West Africa 
(Marx et al., 2001; Santiago et al., 2005). 
 
The HIV-1 pandemic is dominated by HIV-1 group M infections; however, HIV-1 group O 
and HIV-1 group N are associated with regional epidemics, generally limited to Cameroon 
and Senegal in Central Africa (Peeters et al., 1997; MacCutchan, 2006; Yamaguchi et al., 
2006). As mentioned previously, HIV-1 group P has only been identified in France in a 
female immigrant from Cameroon (Plantier et al., 2009). HIV-1 group M was initially only 
limited to the Congo River basin which is the original site of initial zoonotic infections and 
HIV-1 group M diversification. However, HIV-1 group M diversification has since become 
complex and dynamic due to its evolution into numerous subtypes and CRFs (Tebit and Arts, 
2011). The subtypes of HIV-1 form phylogenetic clusters with amino acid variations of 25%-
40%, 20% and 10% in the env gene, gag gene and the pol gene, respectively (Gao et al., 
1998; Brenner, 2007; Santoro and Perno, 2013). Some subtypes were found to be related 
genetically, and linked according to migration patterns between neighbouring countries (Gao 
et al., 1998).  
 
Subtype distribution and epidemiology has indicated that HIV-1 subtype B is predominant in 
Western countries such as in Europe, North America and Australia; while HIV-1 subtype C is 
the predominant subtype worldwide. Nonetheless, due to influx of immigrants from Africa 
and Asia the Western countries have seen increased prevalence of HIV-1 non-B strains 
(Ndembi et al., 2004; Hemelaar et al., 2006; Tebit and Arts, 2011). For example, HIV-1 
subtype A was initially isolated to sub-Saharan Africa but has since been identified in Russia 
(Tebit and Arts, 2011). Diversification of HIV-1 has over the last years led to rapid 
emergence of new subtypes and intermixing of strains and this has resulted in changes in 
geographical distribution and epidemiology (Robertson et al., 2000). For instance, HIV-1 
subtypes A and F have evolved into sub-subtypes A1 and A2 and F1 and F2, respectively 
(Tebit and Arts, 2011). Furthermore, in countries such as Angola classification of HIV-1 sub-
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subtypes A5 and A6 might be required (Bartolo et al., 2009). From the Congo River basin 
westwards towards Nigeria, Côte d’Ivoire, Ghana, Senegal and Mali, the HIV-1 geographical 
distribution is reported to have changed from a previously predominant HIV-1 subtype A and 
D epidemic, to a regional epidemic where CRF02_AG is most prevalent (Tebit and Arts, 
2011). Another country reported to have a high CRF prevalence and diversification is 
Burkina Faso, with CRF06_cpx and SGR’s namely, CRF02_AG/CRF06_cpx having been 
identified (Rambaut et al., 2001; Montavon et al., 2002; Ouedraogo-Traore et al., 2003; Ghys 
et al., 2003; Tebit et al., 2006).  
 
Sub-Saharan Africa and the Congo River basin contain the most diverse HIV-1 strains, as  
virtually all subtypes, sub-subtypes and CRFs were reported in regions such as the DRC and 
Cameroon (Vidal et al., 2000; Tebit et al., 2002; Vidal et al., 2003; Ndembi et al., 2004). 
Initially, east African countries like Uganda, Kenya and Tanzania exhibited the highest HIV-
1 prevalence, but in the late 1990s there was a shift in the epidemic with southern African 
countries namely, South Africa, Lesotho, Botswana and Zimbabwe exhibiting the highest 
regional prevalence (Tebit and Arts, 2011). The epidemic in Southern Africa is mainly due to 
HIV-1 subtype C similar to East Asia including China where HIV-1 subtype B and C CRFs 
(CRF07_BC and CRF08_BC) have been reported (Rambaut et al., 2001; Ghys et al., 2003; 
Tebit and Arts, 2011). South America was reported to exhibit HIV-1 diversity in countries 
like Brazil and Argentina, which have resulted in subtypes B, C and F recombinants (BC and 
BF recombinants).  However, the HIV-1 subtype C epidemic remains the prevalent epidemic 
in South America, especially in Brazil where the incidence of the HIV-1 BC recombinant 
form was reported to be the highest (Soares et al., 2005; Tebit and Arts, 2011). Although 
modest in their global prevalence, HIV-1 unique recombinant forms were reported to be 
abundant in South American countries like Brazil and Argentina; in addition to Nigeria and 
Cameroon in West and Central Africa, respectively. URFs were reported by McCutchan in 
2006 to have 30% prevalence in East African countries like Kenya, Rwanda, Tanzania and 
Uganda (McCutchan, 2006). 
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1.1.5. HIV-1: The virion 
HIV-1 is an enveloped virus with a diameter of approximately 100-120nm and consists of a 
cylindrically shaped core capsid (p24 structural protein) (refer to Figure 1.2) (Gallo et al., 
1984; Montagnier, 1999). The envelope of HIV-1 is a lipid bilayer obtained from the host cell 
plasma membrane during the virus budding process (Arthur et al., 1992); and is studded with 
the viral surface glycoprotein projections; namely, the transmembrane glycoprotein (gp41) 
and the outer trimeric surface glycoprotein gp120 all derived from the precursor protein 
gp160 (Gelderblom, 1991; Turner and Summers, 1999). A matrix shell of the p17 protein 
lines the inner surface of the viral membrane as shown in Figure 1.2 (Turner and Summers, 
1999). 
 
 
Figure 1.2: Schematic diagram of the anatomy of HIV-1. The envelope consists of protruding glycoprotein 
gp120, which stems from the fusion protein gp41. The virus matrix encloses the capsid which protects the two 
copies of genomic RNA, reverse transcriptase, integrase and protease. This figure was obtained from: 
http://www.infohow.org/science/biology-ecology/hiv-viron/ accessed 2015-06-22. 
 
The HIV-1 genome comprises full length diploid linear ribonucleic acid (RNA) of positive 
polarity (Coffin, 1992; Lu et al., 2011), which is stabilised by a ribonucleoprotein complex 
p7. The HIV-1 genome encodes enzymes: protease (PR), reverse transcriptase (RT) and 
integrase (IN) in addition to structural, regulatory and accessory proteins (Gelderblom, 1991; 
Turner and Summers, 1999). In total, HIV-1 comprises of nine genes classified into three 
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functional groups as shown in Figure 1.3. The HIV-1 gag, pol and env genes are classified as 
structural genes; tat and rev genes are classified as regulatory genes; and vpu, vpr, vif and nef 
genes classified as accessory genes (Costin, 2007). The function of each of these genes is 
outlined in Table 1.1. 
 
 
Figure 1.3: The complete HIV-1 genome. The open rectangles represent the coding sequences.   The Gag, Pol, 
and Env genes encode polyproteins which serve as precursors that are cleaved to yield established virus proteins. 
The figure was obtained from Costin, 2007 and illustrates the three main structural genes of HIV-1: gag, pol and 
env. The HIV-1 diagram also depicts regulatory (tat and rev) and accessory (nef, vif, vpr and vpu) genes 
essential for the HIV-1 life cycle. 
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Table 1.1: HIV-1 proteins and their functions.  
 Name Size 
(kDa) 
Function 
Regulatory 
proteins  
Tat/Trans-Activator of 
Transcription 
14  Binds integrated HIV-1 DNA and initiates genome transcription. 
Rev/Regulator of virion 
expression 
18  Regulates viral replication by a controlled translocation of spliced and 
unspliced HIV-1 RNA into the cytoplasm from the nucleus. 
Accessory 
proteins  
Nef/Negative Regulatory 
Factor 
27-35  Down regulates CD4 expression and optimizes T-cell receptor stimuli to the 
favour of optimum virus proliferation. 
Vpr/Viral Protein R 14  Nuclear translocation of the HIV-1 pre-integration complex (PIC), through 
selective cation- ion channel activity. 
Enables HIV-1 replication in non-dividing cells. 
Vpu/Viral Protein Unique 16  Enables the virus budding process from the host cell plasma membrane, by 
interacting with Tetherin.  
Translocation of CD4 proteins toward ubiquitin-mediated degradation in 
lysosomal compartments. 
Vif/Viral infectivity factor 23  Inhibits antiviral activity of the host cell enzyme APOBEC, by translocation 
toward ubiquitin-mediated degradation. 
Gag (Structural 
protein) 
Gag 55  Precursor protein for MA, CA and NC 
Matrix (MA) 17  Binds and targets RNA to the plasma membrane, and incorporates the host 
envelope into virions during assembly. 
Attaches to the inner cell membrane via the myristoylated. 
Capsid (CA) 24  Forms the characteristic core capsid of the virion, which encloses the viral 
genome. 
Nucleocapsid (NC or p7; 
P6,  p1 and p2) 
6-7  p1 determines the rate of Gag proteolysis 
p2 cleavage regulates Gag proteolysis 
Stabilizes the viral RNA genome. 
p6 facilitates virus budding and incorporation of Vpr into virus particles.  
Env (Structural 
protein) 
gp160 160  Inactive precursor molecule for gp120 and gp41. 
gp120 120  Surface component for CD4 receptor binding and co-receptor 
(CCR5/CXCR4) binding. 
gp41 41  Transmembrane component for fusion of virus membrane to host cell 
membrane. 
Gag Pol  
(Structural 
protein) 
Protease/PR 11  Sequential proteolytic processing of the Gag and Gag-Pol polyproteins into 
mature chains. 
Reverse transcriptase/RT 
 (RNAse H/polymerase) 
66 
(p66) 
51 
(p51) 
Conversion of single-stranded viral RNA into double-stranded proviral 
DNA.  
Degrades RNA from RNA/DNA duplexes 
Integrase/IN 32  Responsible for irreversible integration of the viral DNA into the host 
chromosomal DNA, through 3'-processing and the strand transfer reaction. 
The information for the table was compiled from  Graves et al., 1988; Helseth et al ., 1991; Jaskolski et al., 1991; Sherman et al., 1991; 
Werner et al., 1991; Decroly et al., 1994; Bour et al., 1995;  Franzusoff  et al., 1995; Wan and Loh, 1995; Piller et al., 1996; Pettit  et al., 
1998; Bukrinsky and Adzhubei A, 1999; Doms et al., 2000; Montal, 2003; Pierson and Doms, 2003; Strebel, 2003; Levesque et al., 2004; 
Sluis-Cremer et al., 2004; Pugliese et al., 2004; Endo-Munoz., 2005; Fiorentini et al., 2006; Muthumani et al., 2006; Costin, 2007; Miller et 
al., 2007; Stanley et al., 2008; Mascarenhas and Musier-Forsyth , 2009; Blanco et al., 2011; Abraham and Fackler, 2012;  Van Maarseveen 
et al., 2012; Kopietz et al., 2012; reviewed by Solbak et al., 2013 and Banerjee et al., 2014. 
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1.1.6. The HIV-1 life cycle 
The life cycle of HIV-1 is comprised of a number of complex stages such as attachment, 
entry, uncoating, reverse transcription, integration, transcription, translation, assembly, 
budding and maturation, as summarised in Figure 1.4 below. 
 
 
Figure 1.4: A schematic representation of the HIV-1 cycle. The figure was obtained from Costin, 2007 and 
shows attachment of virus to the receptors/and co-receptors which is followed by fusion with cell membrane. 
Virus nucleocapsid entry into cytoplasm precedes reverse transcription; integration occurs within the host-cell 
nucleus. Cellular transcription factors carry out transcription of viral RNAs which are later translated into 
regulatory and structural viral proteins. Daughter virions assemble and bud through cell membrane, following 
maturation through virus protease cleavage. 
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1.1.6.1. HIV-1 entry and tropism 
HIV-1 entry is initiated by virus binding to target CD4+ T cells, which involves CD4 binding 
by gp120, and results in conformational changes that expose the coreceptor binding site of 
the gp120 protein (Doms, 2000; Foti et al., 2002). Following coreceptor binding, the gp120 is 
shed, triggering the gp41 component for fusion. Fusion introduces sequential conformational 
changes in gp41’s native state to a pre-hairpin fusion intermediate, then a fusogenic state and 
finally a post-fusion state. During the fusogenic state the N-heptad repeat (NHR) and C-
terminal heptad repeat (CHR) form a six-helix bundle (6-HB) core structure that allows 
fusion of the viral and host membranes (Lu et al., 1995; Chan and Kim, 1997; Weissenhorn 
et al., 1997; Cha et al., 1998). The fusion process involves the gp41 conformational transition 
following gp120-CD4 binding and coreceptor binding, which leads to pore-formation. This 
step involves the interaction of the HR1 and HR2 peptide motifs which results in the 
formation of a six-helix bundle. However, before the formation of the hairpin structure that 
supports membrane fusion, the gp41 pre-hairpin intermediate structure is formed which 
exposes HR1 and HR2 portions (Wild et al., 1993; Wild et al., 1994; Chen et al., 1995; 
Kliger et al., 2001; Chen et al., 2002; Lalezari et al., 2003; Lazzarin et al., 2003). This 
enables the virus core (p24) entry into the target cell cytoplasm and is, thus, essential to the 
HIV-1 life cycle. 
 
Viral tropism is the ability of viruses to bind specific host cell receptors such as C-C 
chemokine receptor type 5 (CCR5) or the C-X-C chemokine type 4 (CXCR4) receptors 
(Alkhatib et al., 1996; Choe et al., 1996; Deng et al., 1996; Feng et al., 1996; 
Vandekerckhove et al., 2011). Viruses that bind the CCR5 chemokine coreceptor are 
designated R5 variants, and viruses that bind the CXCR4 chemokine receptors are designated 
X4 variants. R5 viruses are common in the early stages of HIV-1 infection, while X4 variants 
emerge later in HIV-1 infection and are associated with clinical disease progression and 
precipitous loss of CD4+ T-cells (Koot et al., 1993; Mass et al., 2000; Sheperd et al., 2008; 
Weisser et al., 2008). Dual tropic viruses, namely, R5X4 use both the CCR5 and CXCR4 
receptors, although preference for one receptor over the other is associated with R5X4 viruses 
(Glushakova et al., 1999; Yi et al., 1999; Li et al., 2001; Coakley et al., 2005).   
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The hypervariable V3 region of gp120 has been identified as the key determining factor of 
viral tropism (Cho et al., 1998; Smyth et al., 1998; Verrier et al., 1999; Li et al., 2001). The 
V3 loop was observed to have a high-affinity CD4 binding site; and the region 
complementary to the CD4 binding site is located in the conserved domains C3 and C4 of the 
gp120 protein (Freed, 2001). Factors such as amino acid sequence, number of basic residues 
and the overall net charge of the V3 loop are known to influence preference in tropism (De 
Jong et al., 1992; De Jong et al., 1992; Harrowe and Cheng-Meyer, 1995; Speck et al., 1997; 
Smyth et al., 1998; Xiao et al., 1998; Kato et al., 1999; Rizzuto and Sodroski, 2000; Wang et 
al., 2000). In addition to the V3 loop, other regions within the gp120 protein such as the V1 
and V2 region are associated with co-receptor usage (Freed, 2001). 
 
1.1.6.2. HIV-1 uncoating   
Subsequent to the HIV-1 host cell fusion and entry, the virus core is then released into the 
host cell cytoplasm and successively the capsid (CA) is uncoated. Uncoating is a poorly 
understood process (Chen et al., 2013; Xu et al., 2013); however, a few theoretical models of 
p24 uncoating exist. The first theory involves dissociation of the viral capsid at the plasma 
membrane immediately after its insertion into the cytoplasm, activated by the immediate 
change in environment in which the viral core capsid finds itself (Dvorin and Malim, 2003; 
Bukrinsky, 2004; Lehmann-Che and Saïb, 2004; Suzuk and Craige, 2007). A second model 
proposes that uncoating and reverse transcription occur at the same time while the capsid is 
being gradually transported towards the nucleus (Warrilow et al., 2009; Arhel, 2010). A third 
model proposes that uncoating only occurs after the core capsid has reached the nuclear 
membrane, upon completion of reverse transcription as this provides optimum stoichiometry 
(Klarmann et al., 1993; Arhel, 2010). Uncoating allows the conversion of reverse 
transcription complexes (RTCs) into pre-integration complexes (PICs) which are integration 
competent (Ellison et al., 1990; Farnet et al., 1990).  
 
1.1.6.3. HIV-1 reverse transcription 
Reverse transcription is an essential step in the life cycle HIV-1, although such proteins as 
nucleocapsid protein (NC or p7), matrix protein, and IN, Tat, Nef and Vif are known to 
contribute in the regulation of the process. Reverse transcription is wholly dependent on the 
catalytic abilities of the viral RT enzyme.  (Sova and Volsky, 1993; Aiken and Trono, 1995; 
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Goncalves et al., 1996; Harrich et al., 1997; Kiernan et al., 1998; Wu et al., 1999; Harrich 
and Hooker, 2002; Sluis-Cremer et al., 2004). HIV-1 RT is an asymmetric heterodimer that 
consists of subunits p66 (560-amino-acid) and a p51 (440-amino-acid) derived from the Gag-
Pol precursor protein (Kohlstaedt et al., 1992). The primary function of RT is to convert 
HIV-1 RNA into double-stranded complementary DNA (Telesnitsky et al., 1997; Jonckheere 
et al., 2000; Sluis-Cremer et al., 2004). RT is a multi-functional enzyme with an 
endonucleolytic ribonuclease H (RNAse H, 15kDa) subunit which catalyses the degradation 
of RNA from DNA/RNA duplexes (Sluis-Cremer et al., 2004). The p66 subunit has an open 
hand conformation with a DNA polymerization site at the centre of the palm which facilitates 
the incoming transfer (t)-RNA binding during transcription (Arnold et al., 1992; Kohlstaedt 
et al., 1992; Kohlstaedt and Steitz., 1992; Jacobo-Molina et al., 1993; Freed, 2000). The p51 
subunit consists of RNaseH (15kDa) and RNA binding sites (Warren et al., 2009).  
 
The process of reverse transcription is initiated when tRNA binds to the primer binding site 
(PBS), of the full length and unspliced RNA template. The PBS is about 200 nucleotides 
downstream of the 5’-end. The host encoded tRNA primer consists of a free 3’-OH group to 
allow DNA elongation (Götte et al., 1999; Sluis-Cremer and Tachdjian, 2008). Once the 
primer is bound on the RNA template, RT recognises the binary tRNA/RNA complex, and 
elongates the primer through its RNA-dependent DNA polymerase activity extending from 
the exposed 3’-OH group until the 5’-end of the HIV-1 RNA (Barat et al., 1989; Isel et al., 
1996; Gotte et al., 1999; Sluis-Cremer and Tachdjian, 2008). This process produces a minus-
strand strong stop DNA, and subsequently the RNA template is hydrolysed through RNaseH 
activity from the RNA/DNA hybrid; leaving the RNA/tRNALys3 intact to serve as primers for 
hybridization of nascent DNA during strand transfer (Schatz et al., 1990; Furfine and 
Reardon, 1991; Gopalakrishnan et al., 1992; Gotte et al., 1995; Gotte et al., 1999; Sluis-
Cremer and Tachdjian, 2008). Elongation of the nascent DNA strand is catalysed by RT’s 
RNA dependent primed DNA polymerase (RDDP) activity, and subsequently RNaseH is 
used to hydrolyse all of the remaining viral segment used as a primer except the polypurine 
tract (PPT), which is used as a primer for the initiation of plus strand DNA synthesis (Huber 
and Richardson, 1990; Wöhrl and Moelling, 1990; Charneau and Clavel, 1991; Klarmann et 
al., 1997). Plus strand DNA synthesis uses the PPT and tRNALys3 as primers, which are later 
removed through RNaseH activity allowing a second strand transfer to occur by interaction of 
the complementary PBS sequences (Huber and Richardson, 1990; Li et al., 1994; Das et al., 
15 
 
1995; Wakefield et al., 1995; Zhang et al., 1998). This results in provirus synthesis from the 
minus and plus strands which then serve as substrates for integration into the host cell 
genome catalysed by IN (Sluis-Cremer, 2008; Sarafianos et al., 2009). 
 
1.1.6.4. HIV-1 proviral integration 
The HIV-1 IN (288 amino acids) is encoded by the pol gene and released from the Gag-Pol 
polypeptide precursor through viral protease-mediated cleavage (Delelis et al., 2008). HIV-1 
IN functions in a multimeric form stabilised by the metal cofactor Zn2+ (Lee et al., 1997); the 
enzyme consists of the N-terminal domain (residues 1-50), the central core domain (residues 
51-212) and the C-terminal domain (residues 213-288). The N-terminal domain consist of a 
zinc binding motif, the central core domain consist of a catalytic active site while the C-
terminal domain has been shown to exhibit DNA binding activity (Kulkosky et al., 1992; 
Zheng et al., 1996; Chen et al., 2000; Woodward et al., 2002; Chiu and Davies, 2004; Levin 
et al., 2009; Esposito and Craigie, 1999). The catalytic activity of HIV-1 IN has been shown 
to require the divalent metal cofactor Mg2+/Mn2+ for efficient 3’-processing and DNA strand 
transfer (ST). However, Mg2+ was shown to induce a more optimum IN catalytic activity in 
vitro (Engelman and Craigie, 1995). 
 
Reverse transcription produces a linear double-stranded proviral DNA which comprises of an 
identical Long Terminal Repeat (LTR) sequence at each end; the proviral DNA serves as a 
recombination intermediate. The viral IN binds the LTR ends and first carries out 3’-end 
processing (3’-EP; Figure 1.5).  The 3’-EP involves cleavage of two terminal nucleotides 
(Cytosine and Adenine) from each 3’-end of the nascent viral cDNA (Craigie, 2001; 
Krishnan and Engelman, 2012). The cleaved proviral DNA is then transported into the 
nucleus as part of the preintegration complex (PIC) through sucrose velocity gradients 
between 160S and 640S after treatment with RNase (Bowerman et al., 1989; Farnet and 
Haseltine, 1990; Karageorgos et al., 1993; Miller et al., 1997). HIV-1 PICs are derived from 
the virion core structures and contain viral IN, RT, Vpr, the host cellular mobility group 
protein HMG 1(Y), LEDGF, and reduced amounts of viral MA (Karageorgos et al., 1993; 
Miller et al., 1997, Shun et al., 2007). The cleaved proviral DNA is then transported into the 
nucleus as part of the preintegration complex (PIC) where IN catalyses the ST reaction 
(Figure 1.5). Strand transfer involves ligation of exposed 3’-OH groups on the proviral DNA 
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onto the cleaved chromosomal DNA (reviewed by Pandey and Grandgenett, 2008). The host 
cell DNA is nucleophilically hydrolysed in a staggered manner during ST, and then the 
exposed 3’-oxygen atoms are used to cleave chromosomal DNA (Fujiwara and Mizuchi, 
1988; Brown et al., 1989; Engelman et al., 1991; Krishnan and Engelman, 2012). The 
resulting DNA recombination intermediate is then ligated on the 5’-phosphates of target 
DNA to the unjointed 5’-ends of chromosomal DNA by host cell ligases to yield the 
integrated provirus (Fujiwara and Mizuchi, 1988; Brown et al., 1989; Engelman et al., 1991; 
Krishnan and Engelman, 2012). 
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Figure 1. 5: A schematic representation of the HIV-1 integrase 3’-processing and strand transfer reaction. The 
figure was obtained from Pommier et al., 2005. (a) 3’ processing is cleavage of the viral DNA immediately 3' 
from the conserved CA dinucleotide. (b) The viral DNA cleavage generates reactive 3'-OH groups on the viral 
DNA ends (red circles). The subsequent reaction is the strand transfer reaction which involves ligation of the 
cleaved 3'-ends into the host-cell chromosome (c-e: blue DNA structure). (d) Each of the 3’-OH viral DNA ends 
react with DNA phosphodiester bonds on the 5’-end of the host genome. This results in a five-base-pair stagger 
across the DNA major groove, a single stranded gap at each junction and two-base flap at the 5'-ends of the viral 
DNA (d and e). (e) Ligation is carried out by cellular repair enzymes which ligate the single stranded gap and 
release of the unpaired 5'-ends of the viral DNA (arrows). 
 
1.1.6.5. HIV-1 transcription and translation 
The integrated HIV-1 provirus then functions as a transcription template for viral RNA and is 
used to encode viral proteins (Freed and Martin, 2001; Karn and Stoltzfus, 2012). RNA 
transcription is initiated by RNA polymerase II (Pol II) binding to the HIV-1 LTR region 
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which harbours cis-acting elements required for RNA synthesis. The LTR consists of regions: 
U3 (for unique, 3’-end), R (for repeated) and U5 (for unique, 5’-end). RNA Pol II binds 
specifically to the U3/R intersection to initiate transcription from the provirus DNA template 
(Ross et al., 1991; Freed, 2001). Initiation of RNA synthesis also requires the Tat protein to 
bind the transactivation response region (TAR), resulting in the recruitment of the human P-
TEFb complex to the TAR bulge. The Tat/human P-TEFb complex binding to DNA leads to 
the phosphorylation of the C-terminal domain of RNA Pol II, resulting in stimulation of RNA 
synthesis (Berkhout et al., 1989; Selby et al., 1989; Freed, 2001; Karn and Stoltzfus, 2012). 
The transcription process produces the generation of a large number of unspliced 
RNAs/mRNA, partially spliced mRNAs (5 kb) and small (1.7 kb to 2.0 kb)-multiply spliced 
mRNAs (Purcell and Martin, 1993; Freed, 2001). The unspliced mRNA function is 
eventually packaged as genomic RNA. The partially spliced RNA is translated into Gag, 
Gag-Pol precursors, Env, Vif, Vpu and Vpr proteins, while the small-multiply spliced 
mRNAs are translated into Rev, Tat, and Nef proteins (Freed, 2001). 
 
1.1.6.6. HIV-1 assembly, budding and maturation 
HIV-1 virus assembly packages components required for virus infectivity such as the two 
positive sense viral RNA strands, cellular tRNALys molecules used as primers for cDNA 
synthesis, the trimeric viral envelope (Env) gp120/gp41 protein, the Gag-Pol polyprotein, the 
PR enzyme , RT enzyme and the IN enzyme (Sundquist and Kräusslich, 2012). The process 
of virion assembly occurs at the host cell plasma membrane within specialised microdomains 
and is mediated by HIV-1 Gag (and Gag-Pol) polyprotein. The HIV-1 Gag polyprotein is 
known to mediate sequential protein-protein interactions at the plasma membrane which 
results in the formation of the virus core-structure and subsequent packaging of genomic 
RNA, and the relevant structural proteins used to create the virus core (Sundquist and 
Kräusslich, 2012). Virus assembly is followed by the budding process mediated by host cell 
endosomal sorting complexes required for transport (ESCRT). The virion acquires its 
envelope from the host cell membrane during budding and thereafter develops a lipid 
envelope interspersed by the viral gp120/gp41 trimeric spikes (Sundquist and Kräusslich, 
2012). During the budding process the Gag polyprotein precursor is cleaved by PR into virus 
constituents MA, CA, NC and p6 proteins forming a mature and infectious virus (Sundquist 
and Kräusslich, 2012). 
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1.1.7. HIV-1 infection mechanisms 
HIV-1 re-infection can occur subsequent to budding when a free and mature virus interacts 
with cells through CD4+ T cell receptor binding (Anderson et al., 2010). Other methods of 
virus infection include cell-to-cell transmission when infected cells are in contact with 
uninfected or infected cells (re-infection) (Mothes et al., 2010). Cell-to-cell transmission may 
also occur through phagocytosis or during cell replication processes such as mitosis (Phillips, 
1994; Noursadeghi et al., 2006). 
 
1.1.8.  Disease progression  
HIV infection is known to progress in phases. The initial acute retroviral syndrome phase is 
associated with high levels of virus production (108 HIV-1 RNA copies/ml), rapidly reduced 
CD4 levels and flu-like symptoms in some patients (Piatak et al., 1993). Eventually the 
immune system reduces virus levels to a virus set point, and the patient enters an 
asymptomatic phase known as the clinical latency stage. Clinical latency is also associated 
with recovered CD4 levels, although CD4 cell count may not return to pre-infection levels. 
During clinical latency, the majority of patients progress to AIDS within 10 years, whereas 
approximately 5% patients remain asymptomatic for over 10 years, and 10-15% of patients 
progress to AIDS within two to five years (Kan, 2007). The symptomatic AIDS phase is 
associated with CD4 cell count below 200/350 cells/mm3; however, even patients with CD4 
cell count between 500 and 1600 cells/mm3 who develop opportunistic infections are 
considered to have progressed to AIDS (Levy, 2007; AVERT, 2014 available on line: 
http://www.avert.org/stages-hiv-infection.htm). In the absence of antiretroviral therapy 
(ART; see below), symptomatic AIDS patients will die within two years of entering this 
phase.  
 
The national consolidated guidelines for the prevention of mother-to-child transmission of 
HIV (PMTCT) and the management of HIV in children, adolescents and adults 
(http://www.sahivsoc.org/upload/documents/HIV%20guidelines%20_Jan%202015.pdf) 
outlines the standardised national eligibility criteria for initiating HIV/AIDS treatment. 
Adults and adolescents are eligible for ART regimens when their CD4 count is ≤500 
cells/mm3 regardless of infections with Hepatitis B virus (HBV), drug sensitive/drug resistant 
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tuberculosis (TB),  Cryptococcus meningitis/TB meningitis and WHO clinical stage (WHO: 
The use of antiretroviral drugs for treating and preventing HIV: 2013). HIV-infected pregnant 
women/breast feeding mothers require fast-track ART within seven days of being eligible. 
Patients with CD4 less than 350 cells/mm3 are placed on a wellness programme to monitor 
their CD4 count every six months and regular counselling. The national eligibility criterion 
for infants and children suggests all children below the age of five years are entitled for ART 
regardless of CD4 count. More importantly, children under the age of 1 year, particularly 
those with TB infection and CD4 counts less than 200 cells/mm3 require fast-tracked ART 
(The South African Antiretroviral Treatment Guidelines; 2013: accessed 2015-01-27). 
 
1.2. HIV-1 treatment 
The discovery of HIV-1 as the causative agent of AIDS resulted in the research and 
development of anti-HIV-1 drugs (Barre-Sinoussi et al., 1983; Popovic et al, 1984); and over 
three decades later approximately 31 drugs have been US FDA-approved for HIV/AIDS 
treatment (reviewed in De Clerq, 2009; De Clerq, 2010; De Clerq, 2013). Suramin and HPA-
23 were the first compounds described to have anti-HIV-1 activity (Mitsuya et al., 1984; 
Rozenbaum et al., 1985; De Clerq, 2013). However, AZT was the first antiretroviral drug 
licensed for HIV/AIDS treatment (Mitsuya et al., 1984; reviewed in De Clerq, 2010; De 
Clerq, 2013); and subsequently didanosine (ddI), zalcitabine (ddC) and stavudine (d4T) were 
approved for clinical treatment of HIV/AIDS (Mitsuya and Broder, 1986; reviewed in De 
Clerq, 2010; Martin et al., 2010).  Current HIV/AIDS drugs used in treatment are classified 
according to their mechanism of action (refer to Table 1.2 below), and the groups include 
nucleoside RT inhibitors (NsRTIs), nucleotide RT (NRTIs), non-nucleoside RT inhibitors 
(NNRTIs), protease inhibitors (PI), HIV-1 co-receptor antagonists (CRA), fusion inhibitors 
(FI) and HIV-1 IN ST inhibitors (INSTIs). 
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Table 1.2: Current US FDA-approved HIV/AIDS antiretroviral drugs*.  
Class Name Abbreviation Mechanism of Action 
 
 
 
 
NRTIs 
Azidothymidine AZT Deoxyribonucleoside analogues that get phosphorylated into diphosphate forms 
(NRTI-TPs) without the 3’-OH group and inhibit transcription by acting as 
chain-terminators of DNA synthesis. 
Didanosine ddI 
Stavudine d4T 
Lamivudine 3TC 
Abacavir ABC 
Emtricitabine FTC 
NsRTIs Tenofovir  TDF 
 
Deoxyribonucleotide analogues that get phosphorylated into triphosphate forms 
(NRTI-TPs) without the 3’-OH group and inhibit transcription by acting as 
chain-terminators of DNA synthesis. 
 
 
NNRTIs 
Efavirenz EFV Non-competitive binding to RTs allosteric site which is ~15 Å from active site. 
This binding changes enzyme conformation to that which doesn’t support RTs 
catalytic activity. 
Nevirapine NVP 
Delavirdine DLV 
Etravirine  ETR 
Rilpivirine RPV 
PI Saquinavir SQV PIs are transition-state analogues comprising of a hydroxyethylene scaffold 
which mimics the normal peptide linkage (cleaved by the HIV protease), which 
cannot be cleaved. Thus once bound competitively to the active site proteolytic 
processing of precursor viral proteins into mature viral proteins is prevented. 
Ritonavir  RTV 
Indinavir  IDV 
Nelfinavir NFV 
Amprenavir AMPL 
Lopinavir  LPV 
Atazanavir  ATV 
Fosamprenavir FPV 
Tipranavir  TPV 
Darunavir DRV 
CRA Maraviroc MVC Interacts with co-receptor CCR5 used by R5 HIV-1 strains. This interaction 
prevents HIV-1 gp120 binding to the co-receptor. 
FI Enfuvirtide T-20 Enfuvirtide is homologous to a segment of the HR2 region of gp41 
corresponding to amino acids 643-678. It binds to HIV-1 gp41 and interferes 
with its ability to approximate the two membranes. FI exploit the gp41 
conformational transition that follows gp120-CD4 binding and co-receptor 
binding, and precedes pore formation. 
INSTIs Raltegravir RAL Inhibit IN ST reaction. Like most nucleotidyltransferase enzymes, IN requires 
two divalent cations bound at the active site for activity. Therefore INSTIs 
described inhibit HIV-1 IN by chelation of bound cations in a dose-dependent 
manner.  
 
Elvitegravir EVG 
Dolutegravir DTG 
*Table 1.2: was adapted from: Goody et al., 1991; De Clerq, 1998; Marchand et al., 2002; De Clerq et al., 
2004;  Pauwels, 2004; Westby et al., 2005; Perros, 2007; Sluis-Cremer and Tachedjian, 2008; De Clerq, 2009; 
Hazuda et al., 2009; Quashie et al., 2012; De Clerq, 2013. 
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1.2.1.1. Highly active anti-retroviral therapy (HAART) 
Combination therapy/HAART regimens have been shown to successfully inhibit the disease 
progression of HIV/AIDS, although the treatment does not eradicate the virus in infected 
patients (Menendez-Arias, 2002; Schulenberg and Le Roux, 2008). However, HAART has 
for many years shown to sustain low plasma (<50 RNA copies/ml) viral load levels 
determined through ultra-sensitive viral load assays (Weller and Williams, 2001; Schulenberg 
and Le Roux, 2008). HAART treatment plans have been effective because of the combination 
of different classes of drugs, which has been observed to effectively delay the emergence of 
antiretroviral (ARV) drug resistant viral strains (Menendez-Arias, 2002; Schulenberg and Le 
Roux, 2008). HAART treatment plans usually consists of a cocktail of three/more ARV 
drugs; either one/two NRTIs/NsRTIs in combination with one NNRTI and/or a PI (Rainey, 
2002; Wynn et al., 2004; Schulenberg and Le Roux, 2008). A fourth agent may be added 
when patients exhibit emergence of drug resistance due to treatment failure. Current first-line 
therapy cocktails approved for use in South Africa include: TDF+FTC/3TC+FDC 
/EFV/NVP, AZT+3TC+EFC/NVP, d4T+3TC+EFV/NVP, ABC+3TC+EFC/NVP and 
TDF+FTC/3TC+EFV with preferences dependent on side effects (psychiatric co-
morbidity/tolerance, neuropsychiatric toxicity, renal disease and anaemia) associated with use 
of particular drugs. Second-line therapy cocktails usually consist of AZT+3TC+LPV/r and 
TDF+3TC (or FTC) LPV/r in patients that exhibit virologic failure to TDF and d4T based 1st 
line regimen. LPV/r can be switched to ATV/r when toxicity is observed (The South African 
Antiviral Treatment Guidelines, Version 14 March 2013). Third-line regimens are available 
through specialist referral and may consist of RAL, DRV and ETR. These become available 
once patients display virological failure during second-line therapy, and the regimen is 
adjusted according to HIV drug resistance genotypic interpretation (Schulenberg and Le 
Roux, 2008; The South African Antiretroviral Treatment Guidelines, Version 14 March 
2013). 
 
The World Health Organization (WHO) guidelines for scaling up ART with a focus on 
resource-limited settings was an indication of clinically integrated thinking aimed at curbing 
the severity of the HIV/AIDS epidemic in remote settings (WHO, 2002; Coetzee et al., 
2004). It has since been reported that approximately 61% (57%-66%) of people eligible for 
ARV treatment in low- and middle income countries had obtained HIV/AIDS treatment; in 
total 12.9 million people living with HIV/AIDS were receiving ARVs in 2013 (UNAIDS Fact 
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Sheet, 2014). The expansion in ARV treatment produced clear health gains as a reduction in 
the number of new HIV-1 infections was observed in areas were ARV treatment was scaled-
up. For instance, an estimated 1.5 million [1.4 million–1.7 million] people died from 
HIV/AIDS-related deaths in 2013, compared to the 2.4 million [2.2 million–2.6 million] in 
2005 (UNAIDS Fact Sheet, 2014). The five-year ART rollout implemented in 2003 by the 
South African government had already resulted in an estimated increase of 11.3 years in life 
expectancy in the KwaZulu-Natal province by year 2011 (UNAIDS, 2013). 
 
1.3. HIV-1 IN drugs 
1.3.1. Early anti-HIV-1 IN agents 
The history of the discovery of IN inhibitors (INI) comprises of a diverse group of different 
molecules such as peptides, nucleotides, DNA complexes, natural products and rationally 
designed compounds (Jing and Xu, 2001; Singh et al., 2001; Sluis-Cremer et al., 2002; 
Maurin et al., 2003; Brigo et al., 2005). Some of these molecules showed potential as INI and 
progressed into pre-clinical trials, but their development was halted by in vivo toxicity and 
non-specificity (de Soultrait et al., 2003; Gupta and Nagappa, 2003; Maurin et al., 2003). Of 
note were a few 4-aryl-2-,4-diketobutanic acid (DKA) that demonstrated notable anti-HIV-1 
activity in cell culture from a large library of 250 000 compounds from Merck and Co; and in 
vitro selection and sequencing of the outgrown viruses showed resistant mutations within the 
IN gene, therefore confirming their mechanism of action as INIs (Hazuda et al., 2000). L-
731988 was one of these DKAs that demonstrated specificity through inhibition of the HIV-1 
IN ST reaction (IC50 = 80 nM) in comparison to 3’-processing reaction (IC50 = 6 µM) 
(Hazuda et al., 2000). The inhibition of the ST reaction was described to be by chelation of 
bound cations within the D64 D116 E152 motif by a prototype DKA namely, 1-(5-
chloroindol-3-yl)-3-hydroxy-3-(2H-tetrazol-5-yl)-propenone (5-CITEP) within the IN active 
site (Goldgur et al., 1999; Derwent, 1999; Marchand et al., 2002). The backbone of 5-CITEP 
served as a template for the design and development of INI with enhanced efficacy, 
specificity, tolerability and bioavailability such as S1360. S1360 advanced into clinical trials 
but its success was halted by its short half-life in vivo due to rapid glucuronidation 
(Rosemond et al., 2004). 
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1.3.2. First generation clinically approved INIs 
RAL is a pyrimidine carboxamide developed using the backbone 5-CITEP variations namely, 
L-731988 and L-870812 (Summa et al., 2008). INIs  L-731988 and L-870812 were optimized 
in Merck pharmaceuticals by substituting the β-diketo acid chemical moiety to various forms 
using ketones, diketones and naphthyrine carboxamides which resulted in enhanced chemical 
stability (Lataillade and Kozal, 2006) of one N-[(4-fluorophenyl) methyl]-1,6-dihydro-5-
hydroxy-1-methyl-2-[1-methyl-1-[[5-methyl-,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-
oxo-4-pyrimidine carboxamide monopotassium salt (RAL) (Cocohoba et al., 2008; Figure 
1.6). RAL was later approved by the US FDA in October 2007 and now forms part of third-
line ART salvage treatment in South Africa in combination with ETV and DRV 
(http://www.avert.org/starting-monitoring-switching-hiv-treatment.htm). 
 
Figure 1. 6: The chemical structure of RAL. RAL is produced by Merck & Co and exhibits potent anti-HIV-1 
IN activity (IC50 =2-7 nM), and anti-HIV activity (EC90 = 8.9 nM). The chemical structure and data were 
obtained from a review by Metifiot et al., 2010. 
 
Further optimizations of DKAs by the Japan Tobacco Company led to four variations of 4-
quinolone-3-glyoxylic acids which consisted of a single pair of coplanar ketone and 
carboxylic groups, designated according to their functional DKA motif (Sato et al., 2006; 
Wills et al., 2012). One of these variations of 4-quinolone-3-glyoxylic acids contained only a 
β-ketone functional group and a carboxylic acid functional group, and exhibited good HIV-1 
IN ST inhibition (IC50 = 1.6 μM) and was used as the backbone for 6-[(3-chloro-2-
fluorophenyl)methyl]-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxoquinoline-3-
carboxylic acid (EVG) synthesis (Figure 1.7) which demonstrated high potency  (IC50 = 7.2 
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nM) in direct anti-HIV IN assays and good anti-HIV-1 (EC50 = 0.9 nM) inhibition (Sato et 
al., 2006; Al-Mawsawi et al., 2008). In 2012, the second first generation INI, EVG obtained 
US FDA approval as a component of the quad pill Stribild. 
 
 
Figure 1. 7: The chemical structure of EVG which is produced by Gilead Sciences and Japan Tobacco Inc. The 
chemical structure was obtained from a review by Metifiot et al., 2010. 
 
1.3.3. Stribild 
Fixed dose drug combinations (FDCs) have been introduced, and these include Combivir® 
(AZT+3TC), Trizivir® (AZT+3TC+ABC), Truvada® (FTC+TDF), a once daily combination 
pill Atripla® (TDF+FTC+EFV) approved in 2006, Complera®/Eviplera®  (TDF+FTC+RPV) 
approved in 2011, and the only INI containing FDC, a “quad” pill designated Stribild 
(TDF+FTC+EVG+cobicistat (COBI)) approved in August 2012 (reviewed in De Clerq, 
2013). Other quad pills currently in clinical trials contain (i) ATV+COBI+TDF+FTC and (ii) 
DRV+COBI +TDF+FTC (iii) EVG+COBI+TDF+FTC (reviewed in De Clerq, 2013). 
 
Stribild contains 150 mg EVG, 200mg FTC, 300mg TDF and a pharmaco-enhancer without 
anti-HIV activity;  COBI (150 mg) (https://www.stribild.com/). As mentioned in Table 1.2, 
EVG is an INSTI that binds the IN catalytic core domain and halts HIV-1 proviral DNA 
integration (DeJesus et al., 2006; Hicks and Gulick, 2009; Deeks, 2013;  Messiaen et al., 
2013); and virus proliferation of  HIV-1 clinical isolates A, B, C, D, E, F, G, O  and some 
NRTI, NNRTI and PI resistant virus isolates. Stribild was approved following observations of 
EVGs synergistic effects in combination with NRTIs (ABC, ddI, FTC, 3TC, d4T, TDF and 
AZT), NNRTIs (EFV, ETR and NVP), PIs (APV, ATV, DRV, IDV, LPV, NFV, RTV, 
26 
 
SQV), FI (ENF) and the CCR5 receptor antagonist (MRV). EVG exhibited additive effects in 
combination with RAL and antagonistic effects against other HIV-1 drugs are yet to be 
reported (Gilead Sciences Inc. US prescribing information for Stribild®, 2013; European 
Medicines Agency, 2013). The FTC in Stribild is a fluorine-containing cytidine analogue that 
inhibits HIV-1 RT following phosphorylation by cellular kinases into an active 5’-
triphosphate that terminates host cell DNA synthesis/RNA transcription (Darque et al., 1999; 
Rousseau et al., 2001; Goodman et al., 2011). TDF is also an acyclic nucleoside phosphonate 
that inhibits HIV-1 RT following diester hydrolysis and phosphorylation by cellular kinases 
into an active metabolite TDF-diphosphate. TDF-diphosphate inhibits HIV-1 RT through 
competition with the purine nucleoside, adenosine, leading to a halted viral DNA strand 
elongation (reviewed by De Clercq, 2013). 
 
COBI is an inhibitor of enzymes involved in the metabolism of EVG and PIs (ATV and 
DRV). The metabolism of EVG involves the cytochrome P450 enzyme and UDP 
glucuronosyltransferase (UGT) 1A1/3 which catalyses glucuronidation (Ramanathan et al., 
2008; Adams et al., 2012; Olin et al., 2012; Deeks, 2013). COBI was observed to extend the 
bioavailability and half-life of EVG by 21 hours (Adams et al., 2012; Olin et al., 2012). 
COBI also inhibits p-glycoprotein, BCRP, and OATP1B1/1B3 involved in substrate 
transportation (Lepist et al., 2012; Custodio et al., 2012). However, COBI similarly requires 
phosphorylation by cellular enzymes into an active intermediate by CYP3A4 and to a lesser 
extent CYP2D6 (Ernest et al., 2005; Xu et al., 2010; Deeks et al., 2014). 
 
1.3.4. Early second generation INIs  
RAL and EVG are associated with a low to moderate genetic resistance barrier in vitro and in 
AIDS patients, as a result of the emergence of single mutations or a combination of primary 
and secondary mutations (Geretti et al., 2012; Mesplède et al., 2013; Quashie et al., 2013; 
Grobler and Hazuda, 2014). This led to renewed research focus on the development of second 
generation INSTIs with a high genetic resistance barrier and activity against RAL and EVG 
resistant virus isolates. Initial developments of second generation INSTIs included the 
discovery of a tricyclic 10-hydroxy-7, 8-dihydropyrazinopyrrolopyrazine-1,9-dione 
compound which served as parent compounds for INI MK-2048 (Vacca et al., 2007; Al-
Mawsawi et al., 2008). MK-2048 exhibited direct IN strand transfer inhibition and tissue 
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culture anti-HIV-1 activity (EC95 <50nM) (Vacca et al., 2007), but its progression was 
halted by poor pharmacokinetic properties observed during clinical development (Vacca et 
al., 2007; Al-Mawsawi et al., 2008; Pandey et al., 2010; Goethals et al., 2011; Van 
Wesenbeeck et al., 2011). 
 
1.3.5. DTG and S/GSK-1265744 
DTG (Figure 1.8) was developed along with S/GSK-1265744 which served as a back-up 
drug. Although S/GSK-1265744 exhibited good anti-HIV-1 efficacy, pharmacokinetic 
properties and exhibited good tolerability in patients, its development was halted by the US 
FDA approval of DTG (Highleyman, 2009). DTG was discovered by Shionogi 
Pharmaceuticals, Japan and further developed through a joint venture between Shiniogi-ViiV 
Healthcare-GlaxoSmithKline (Eron et al., 2010; Yoshinaga et al., 2010). DTG was developed 
with the primary objective of finding a drug that allowed once-daily dose (<100 mg) without 
the need for pharmacoenhancers, acceptable drug-drug interactions, and without cross-
resistance (and a higher genetic resistance barrier) to RAL and EVG (Blanco et al., 2011; 
Jonhs et al., 2013). 
 
 
 
Figure 1. 8: The chemical structure of DTG. DTG has potent anti-HIV-1 IN activity of approximately 2.7 nM 
and anti-HIV-1 activity of 2 nM in tissue culture. The chemical structure and data were obtained from a review 
by Metifiot et al., 2010. 
 
1.4. Antiretroviral drug resistance  
Treatment of HIV/AIDS with multiple drugs/HAART suppresses virus replication more 
effectively than monotherapy; and effective suppression of HIV-1 proliferation results in the 
“arrest” of emerging new drug resistant variants (Clavel and Hance, 2004). The use of 
HAART has proven remarkably effective in controlling the progression of HIV/AIDS, and is 
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associated with reduced AIDS-related mortality rates and a prolonged life span of AIDS 
patients. These successes are, however, limited, by the emergence of antiretroviral drug 
resistant isolates (termed acquired resistance) during HAART treatment (Palella et al., 1998; 
Clavel and Hance, 2004). The emergence of drug resistant isolates has also been associated 
with transmission of such strains, which threaten the effectiveness of HAART in newly 
infected HIV/AIDS patients (termed transmitted drug resistance).  
 
HIV infection is associated with the inevitable emergence of diverse quasispecies within 
infected individuals harbouring drug resistance mutations (Saag et al., 1988; Wainberg et al., 
1996). Factors known to result in HIV-1 drug resistance include the low-fidelity of RT which 
is notoriously error prone. RT introduces on average one mutation per viral genome 
transcription, in combination with drug selection and immune pressure created during long-
term patient treatment (Roberts and Bebenek, 1988; Preston et al., 1992; Wainberg et al., 
1996). Most of the mutations obtained are base substitutions, but duplications, insertions and 
recombination have been reported (Coffin, 1995; Malim and Emerman, 2001; Bonhoeffer 
and Sniegowski, 2002; Clavel and Hance, 2004; Levy et al., 2004). Retroviral recombination 
occurs during coinfection of a cell by two/more viral isolates; and involves transfer of the 
nascent DNA provirus from one RNA template to that of another isolate, therefore resulting 
in mosaic DNA provirus (Levy et al., 2004). Studies have shown that RT alternates between 
RNA strands of distinct isolates on average three times per replication cycle and this capacity 
is believed to enhance the evolution of drug resistance mutations considerably (Jetzt et al., 
2000; Zhaung et al., 2002; Bretscher et al., 2004). The development of HIV-1 drug resistant 
variants over time is associated in part with the eventual failure of treatment strategies 
(Richman et al., 1994; Wainberg et al., 1996). Mutations can confer some selective 
advantage to the virus, such as a decrease in its susceptibility to an antiretroviral agent 
(Clavel and Hance, 2004). However, certain strains such as HIV-2 exhibit natural resistance 
to most NNRTIs; likewise some HIV-1 non-B subtypes are naturally less susceptible to 
PIs/NNRTIs than HIV-1 subtype B, against which most of the ARV drugs were developed 
(Shafer et al., 1997; Descamps et al., 1997; Palmer et al., 1998; Descamps et al., 1998; 
Witvrouw et al., 1999). 
 
The control of acquired and transmitted HIV drug resistance can be achieved through 
evidence-based treatment strategies which include the uninterrupted rational use of ARVs 
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with programmatic surveillance and monitoring. This will allow tracking of global drug 
resistance trends and rational choices in containment activities in areas with increasing drug 
resistance rates and high prevalence (WHO, 2014). 
 
1.5. The mechanisms of HIV-1 drug resistance 
1.5.1.1. RTI resistance 
The mechanisms of resistance to nucleoside/tide analogues are associated with impaired 
analogue incorporation into the host DNA. In the case of M184, mutations are located within 
the catalytic site of RT, and are typically replaced with valine (M184V) which interferes with 
proper positioning of the 3TC triphosphate within the catalytic site; thus resulting in 
resistance (Sarafianos et al., 1999). Another resistance mechanism involves the removal of 
the inserted nucleoside/tide analogue from a terminated DNA chain; and these are termed 
“thymidine analogue mutations (TAMs).” The development of TAMs is known to be 
catalysed by coenzyme adenosine triphosphate (ATP)-or pyrophosphate which 
phosphorylates the inserted chain terminator from the 3’-end of the DNA strand (Arion et al., 
1998; Meyer et al., 1999). ATPs and pyrophosphates are abundant in human lymphocytes 
which do not participate in the DNA-polymerization reaction, but the structure of the RT 
expressing TAMs facilitates their attack of the phosphodiester bond adjacent to the 
incorporated analogue (Boyer et al., 2001; Chamberlain et al., 2002). 
 
NNRTIs are designed to bind with high affinity to the hydrophobic pocket in close proximity 
to the RTs catalytic domain. This binding changes RTs conformation such that the enzyme 
flexibility is inhibited, thereby hindering the RT DNA polymerization capacity (Esnouf et al., 
1997). All NNRTI resistant mutations emerge within the hydrophobic pocket such that 
NNRTI affinity is reduced considerably (Boyer et al., 1993; Richmann et al., 1994; Esnouf et 
al., 1997; Bacheler et al., 2000; Ren et al., 2001). 
 
1.5.1.2. PI resistance 
PIs are designed to exhibit high affinity for the HIV-1 PR active site, as they are structurally 
related to viral peptides normally recognized and cleaved by the PR enzyme. PIs lack a PR 
cleavage site; therefore, their active site binding inhibits PR catalytic activity through 
prolonged occupation of site (Roberts et al., 1990; Erickson et al., 1994). PI drug resistance 
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mutations (i.e. V82A) are associated with reduced amino acid residue size, which therefore 
only allows binding of the natural viral substrate (Prabu-Jeyabalan et al., 2002). Therefore, 
because PIs large size contributes to their maximum binding affinity; the reduced active site 
size due to mutations ensures non-binding of PIs. The natural substrates of PR are variable in 
size and have a lower affinity for the catalytic site, which promotes ordered sequential 
cleavage of the polyproteins required for proper assembly of virions (Clavel and Allan, 
2004). 
 
1.5.1.3. Entry inhibitor resistance 
The gp41 protein is considered a highly conserved region of the envelope glycoprotein, with 
minor differences on the HR1 binding site among HIV-1 group M subtypes (Cilliers et al., 
2004; Aghokeng et al., 2005; Holguin et al., 2007). The development of T-20 resistance has 
been associated with mutations within the highly conserved amino acid triad within the HR1 
region at positions: 36-38 and 36-45 with varying levels of resistance (Poveda et al., 2002; 
Greenberg and Cammack, 2004; Mink et al., 2005). T-20 resistance mutations are associated 
with reduced binding effectiveness between the HR2/HR1 interactions, a prerequisite for the 
fusion process (Poveda et al., 2002).  
 
HIV-1 resistance to CCR5 antagonists has been observed both in vitro and in vivo; and 
remains associated with emergence of multiple sequence mutations within the V3 region 
which results in dependency on the CCR5 N-terminus (NT) (Tsibris et al., 2008; Berro et al., 
2009; Nolan et al., 2009; Ogert et al., 2010). Another, but rare, pathway involves mutations 
within the fusion peptide (FP) of the gp41 protein; but in all cases, resistant viruses gain cell 
entry through a free/inhibitor bound CCR5 receptor (Pugach et al., 2007; Anastassopoulou et 
al., 2009). 
 
1.5.1.4. INSTI resistance 
The majority of INSTI resistance mutations described emerge within the catalytic core 
domain of IN and are associated with decreased drug susceptibility, as shown in Table 1.3. 
Since the focus of this work is INSTI resistance, the mutations are described in detail. 
Mutations known to confer resistance to RAL have been described at positions 143, 148 and 
155 within the putative INI binding pocket, and each represents mutually distinct and non-
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overlapping pathways for RAL resistance (Goethals et al., 2008; Fransen et al. 2009; Malet et 
al., 2009; Whitmer and Danovich, 2009; Kobayashi et al., 2011; Fransen et al., 2012; 
Fransen et al. 2012). RAL and EVG were observed to exhibit cross-resistance as both drugs 
select for similar resistant mutations (N155H, Q148RHK and E92Q); with the exception of 
T66I only selected through EVG treatment (Goethals et al., 2008; Goodman et al., 2008; 
Malet et al., 2009). Other amino acid substitutions that have been selected during INSTI 
treatment both in vivo and in vitro include: V72I, L74I/M, E92Q, T97A, F212Y, E138K, 
G140S/A, V151I, E157Q, G163R, I203M and S230R (Low et al., 2009; Malet et al., 2009). 
To date, all RAL and EVG resistant isolates exhibit susceptibility to DTG; with Q148HRK 
being an exception. The Q148HRK substitutions have been shown to display limited 
resistance to DTG in combination with L101I, T124A, G118R, R263K and S153Y 
(Kobayashi et al., 2011; Mesplède et al., 2012; Quashie et al., 2012; Wares et al., 2014); and 
this suggests additional secondary mutations may induce considerable resistance to DTG 
(Mesplède et al., 2012).  Combinations shown to exhibit notable resistance to DTG include 
E138K/Q148K and Q148R/N155H, while virus isolates with combinations as follows: 
Q148R/ G140CS and T66K/L74M and I151L have been reported to exhibit moderate 
reduction in DTG susceptibility (Kobayashi et al., 2011). Other DTG selected mutations 
include substitutions at position 153 which include S153F, S153Y; and S153 in combination 
with other mutations (L101/IS153F, T124A/S153Y and L101IT/124A/S153F) of unknown 
relevance (Kobayashi et al., 2011).  
 
Along with known INSTI resistance pathways N155H, Q148HRK, and Y143RC; accessory 
mutations such as E92Q and G140S are associated with recovery of reduced viral 
fitness/replication capacity (RC; Malet et al., 2009; Hu and Kuritzkes, 2010; Canducci et al., 
2010; Hatano et al., 2010). In isolated instances, INI resistant mutations have been observed 
to revert (or back-mutate); which demonstrates the dynamic nature and complexity of INI 
resistance development as the virus then regains the lost RC (Ferns et al., 2009; Canducci et 
al., 2010). 
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Table 1.3: Fold changes in susceptibity to major and alternative resistance pathways to 
current INSTIs. Data was compiled from Abram et al., (2013), Quashie et al., (2013) and 
Wainberg and Han (2015). 
  Fold Resistance 
Resistance Pathways  RAL EVG DTG 
Y143 pathway Y143C <10 <2 <2 
Y143H 2.1 1.2 0.9 
Y143R <50 <2 <2 
T97A/Y143C >100 <2 <2 
T97A/Y143R >100 <2 <2 
L74M/T97A/Y143G <50 - <2 
L74M/T97A/E138A/Y143C <20 - <2 
T97A 1.2 2.4 0.5 
N155 pathway N155N <50 50 <2 
E92Q/N155H <100 >100 <10 
L74M/N155H <50 <50 <2 
Q148 pathway Q148H <20 <10 <2 
Q148K <100 <100 <2 
Q148R <50 <100 <2 
E138K/Q148H <10 <20 <2 
E138K/Q148K >100 >100 <10 
E138K/Q148R >100 >100 <10 
G140S/Q148H >100 >100 <20 
G140S/Q148K <10 <100 <2 
G140S/Q148R >100 >100 <10 
E138A/G140S/Y143H/Q148H >100 - <50 
R263K pathway R263K <10 <10 <50 
H51Y/R263K 3-5 3 4-6 
G118R pathway G118R <10 <2 <10 
H51Y/G118R - - - 
L74M/G118R <50 <10 - 
G118R/E138K <10 <2 <10 
E138K <10 <10 <10 
T66 pathway T66I <2 <10 <2 
T66A <2 <10 <2 
T66K <10 <100 <50 
T66I/L74M <10 <50 <2 
T66K/L74M <50 <100 <10 
T66K/R263K <2 <100 - 
E92Q pathway E92Q <10 <50 <10 
E92G 1.5 9 1 
E92Q/S147G <10 >100 - 
S147G <2 <10 1 
S153 mutations S153F <2 <10 <2 
 S153Y <2 <10 <10 
- No information.  
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1.5.1.5. Effect of resistance mutations on RC 
The inevitable emergence of ARV drug resistance is often associated with incompletely 
suppressive drug regimens or treatment interruptions by patients. It is generally 
acknowledged that the emergence of most ARV drug resistance mutations will decrease the 
RC of HIV-1. Interestingly, treatment interruption by patients infected with multi-drug 
resistant HIV-1 has been reported to result in the replacement or outgrowth of resistant 
viruses by wild-type (WT) virus. Furthermore, in the same patients a decreased CD4+ T-cell 
count was observed which suggests a greater replicative/pathogenic potential by WT viruses 
(Deeks et al., 2001; Clavel and Hance, 2004). Thus, in the absence of drugs, as ARV drug 
resistant viruses revert back to WT, the viral RC can be “restored”. 
 
The emergence of ARV drug resistance in HIV-1 occurs by the introduction of mutations 
within the pol gene (or other relevant gene targets), which have been shown to modify key 
viral proteins which results in various deleterious effects (Barbour et al., 2003; Clavel and 
Hance, 2004), and are often also associated with reduced RC/viral fitness and reduced 
pathogenicity (Deeks et al., 2001; Prado et al., 2005). For example, with the inhibitors 
targeting the RT, PR or IN enzymes, the loss in virus RC is often owed to structural changes 
in these enzymes expressed from the mutated pol gene which results in inefficiencies in 
binding capacity to natural substrates and loss in enzyme catalytic efficacy (Dauber et al., 
2002; Malim et al., 2001). Nonetheless, the cost of replication impairment has been observed 
to vary among virus subtypes and clinical virus isolates from drug-naïve patients (infected 
with viruses carrying resistant natural polymorphisms) resistant to a particular ARV 
treatment (Wrin et al., 2001; Cingolani et al., 2002; De Luca et al., 2005). Such impaired 
viral/enzyme functions have been shown to be partially corrected by secondary mutations that 
compensate for the decreased viral/enzyme fitness (Kaplan et al., 1994; Nijhuis et al., 1999; 
Clavel and Hance, 2004; Lataillade et al., 2007).  
 
Several NRTI, NNRTI and PI are associated with reduced viral fitness. For instance, NRTI 
resistance mutations M184IV, M41L, L210W, T125Y, K65R and L74V are known to exhibit 
reduced virus fitness (reviewed by De Luca, 2006). Interestingly, the presence of a single 
primary drug mutation such as M184V (confers resistance to 3TC) is associated with a lower 
incidence of TAMs and with increased susceptibility to other RT inhibitors such as AZT in 
viral variants that contain drug resistance mutations to AZT during simultaneous treatment 
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with 3TC. The M184V mutation also has an effect on RT fidelity and processivity, reducing 
spontaneous mutagenesis and impacting on viral replication fitness, respectively. NNRTI 
resistance mutation V106A, Y188C and G190S are also associated with lower viral fitness, 
but resistance mutations K103N and Y181C exhibit a trivial reduction in virus fitness 
although still comparable to WT virus (reviewed by De Luca, 2006).   
 
Considerable loss in virus RC has been reported in clinical isolates/molecular clones 
containing PI resistance mutations D30N, M46I/L, G48V, I50V, I54V, V82A/T, I84V, 
N88DS and L90M. Substitution L90M is associated with resistance to SQV and was 
established to exhibit less RC when compared to NFV resistant D30N isolates (Martinez-
Picado et al., 1999; Resch et al., 2002; Prado et al., 2002). FI (T20) resistance has also been 
associated with reduced virus fitness, as a result of resistance-associated substitutions 
introducing conformational changes in gp41 that lead to delayed and reduced efficiency in 
the fusion process (Reeves et al., 2005). Reduced virus/IN fitness has been reported as a 
result of selection of INSTI major resistance mutations (i.e. N155H and Q148H) within the 
pol gene following ARV treatment (reviewed by Quinones-Mateo 2008; Hu and Kuritzkes, 
2010; see section 1.5.1.6 below). 
 
Drug susceptibility/resistance scores remain the most important determinants of treatment 
responses during the clinical management of patients. South Africa has recently introduced 
the use of an INSTI as a component of the 3rd line salvage regimen. There is currently limited 
knowledge on the emergence of INSTI drug resistance in this treatment experienced HIV-1 
subtype C infected population. Thus, a better understanding of the impact of antiretroviral 
drug-resistance mutations on HIV-1 RC and their contribution to levels of fold resistance are 
critical to derive maximum clinical benefit in our resource limited setting. 
 
1.5.1.6. Effect of INSTI selected resistance mutations on RC and IN fitness 
All IN resistance mutations are associated with reduced HIV-1 RC and reduced IN 3’-P/and 
ST as shown in Table 1.4. Abram et al., (2013) reported on the impact of primary EVG 
resistance-associated mutations on viral RC using single mutations T66AIK (69%/84%/9%), 
E92GQ (6%/64%), T97A (68%), Y143CHR (49%/78%/75%), Q148HKR (54%/36%/70%) 
and N155H (72%). Furthermore, double mutations T66I/E92Q, T66I/Q148R, T66I/N155H, 
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E92Q/Q148R, E92Q/N155H and Q148R/N155H exhibited 25%, 20%, 15%, 4%, 40% and 
15% RCs, respectively (Abram et al., 2013). Preceding studies on corresponding mutations 
selected by RAL have described similar results (Buzon et al., 2008; Goethals et al., 2008; 
Shimura et al., 2008; Fransen et al., 2009; Nakahara et al., 2009; Quercia et al., 2009). In 
addition, RAL and EVG primary drug resistant substitutions are often associated with 
subsequent emergence of secondary mutations known to play a compensary role by 
enhancing RC/enzymatic activity (reviewed by Mesplède and Wainberg, 2014). However, 
selection of mutation R263K with DTG is not only associated with diminished viral RC and 
enzymatic 3’-P/ and ST activity; but the secondary mutations selected in combination with 
R263K are also associated with impaired (>80%) virus RC, and further diminution of HIV-1 
IN activity (reviewed by Mesplède and Wainberg, 2014). This raises the possibility that low-
level resistance against DTG might not lead to virological failure or adverse clinical 
consequences; as such viruses are truly at a severe replication disadvantage in comparison 
with wild-type HIV-1 (reviewed by Mesplède and Wainberg, 2014).  
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Table 1.4: Mutant 3’-processing, strand transfer activity and replication capacity with respect 
to wild-type integrase enzyme and virus. The data was obtained from a review by Métifiot et 
al., 2010. 
 IN Virus 
Mutations 3’-P ST RC 
H51Y - 40-80% - 
H51Y/E92Q/S147G - 10-40% - 
H51Y/E92Q/S147G/E157Q - 40-80% - 
T66A 10-40% 40-80% 40-80% 
T66I 80-100% 80-100% 40-80% 
T66I/E92Q - 0-10% - 
L74M 80-100% 80-100% - 
E92Q 80-100% 80-100% 40-80% 
E92Q/S147G - 10-40% - 
E92Q/N155H - - 40-80% 
E138K/Q148HRK - - 40-80% 
G140S 80-100% 10-40% 40-80% 
G140A 40-80% 10-40% - 
G140S/Q148H 40-80% 80-100% 80-100% 
G140S/Q148K 40-80% 10-40% 40-80% 
G140S/Q148R 0-10% 10-40% 40-80% 
G140A/Q148H 0-10% 10-40% 10-40% 
G140A/Q148K 0-10% 0-10% 40-80% 
G140A/Q148R 10-40% 10-40% 40-80% 
G140S/Q148H/S230N - - 80-100% 
Y143R 10-40% 40-80% 10-40% 
Y143C 10-40% 10-40% 10-40% 
Y143R/Q148H/S230N - - 40-80% 
S147G - 10-40% - 
Q148K 0-10% 10-40% 10-40% 
Q148R 10-40% 10-40% 40-80% 
Q148H 0-10% 10-40% 40-80% 
Q148H/N155H - - 10-40% 
Q148K/G163R - - - 
N155H 80-100% 80-100% 40-80% 
E157Q - 40-80% - 
S230R 80-100% 80-100% - 
-: No information; 3’-P: 3’-processing activity; ST: strand transfer activity; RC: virus replication capacity;  
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1.6. The significance of this study 
HIV-1 subtype B has been the subject of most ARV drug resistant research with respect to 
INSTI (and all other ARVs), due to its predominance in those countries in which ARVs first 
become available (Wainberg and Brenner, 2012). As a result, data on non-C HIV-1 drug 
resistance to the new class (INSTI) of drugs is limited. HIV-1 naturally varies in genetic 
content by as much as 35% among subtypes, and variation is higher in some areas of the 
genome, particularly Env: 25-40%, and lower within the Pol-Gag gene: 8-10% (Brenner, 
2007; Santoro and Perno, 2013). Inter-subtype variability in IN is relatively low: 8-12% at the 
amino acid level (Brenner, 2007; Santoro and Perno, 2013; Martinez-Cajas et al., 2009; Bar-
Magen et al., 2009; Bar-Magen et al., 2010). Interestingly, subtype-specific amino acid 
differences are often found in close proximity to known ARV drug resistance sites.  
 
Since its introduction in the government sector in April, 2004, HAART has dramatically 
increased the life expectancy of people infected by HIV-1 in South Africa. However, the 
success of HAART is limited by the emergence of antiretroviral drug resistance which results 
in virological failure (Ajose et al., 2012). Thus, the May 2013 addition of the INSTI, RAL to 
the third line regimen available in the South African public sector represented an important 
advance for the treatment of ARV treatment-experienced patients. Moreover, the latest FDA 
approval of EVG and DTG, suggests these INSTIs are likely to be approved by the Medicines 
Control Council of South Africa in the near future. RAL, EVG and DTG resistance data is 
limited for HIV-1 subtype C which is highly endemic in sub-Saharan Africa (UNAIDS, 
2011), and particularly in South Africa. IN mutations T97A, E157Q, V165I and V72I have 
been reported in therapy naïve South African patients from the Charlotte Maxeke 
Johannesburg Academic Hospital (Fish et al., 2010). Additional IN mutations, specifically 
G163R and V151I previously associated with RAL use, were also reported in cohorts 
recruited for the AIDS Vaccine Integrated Project (AVIP) study at the Baragwanath Hospital 
in Johannesburg (Papathanasopoulos et al., 2010). Minor resistance mutations (L74M, 
Q95K), and polymorphisms (Q95P, E157K, I203M and R263S) associated with RAL 
resistance have been reported in six different subjects (Bessong and Nwobegahay, 2013); but 
to date no major/accessory INSTI associated resistance mutations have been reported in 
Southern Africa particularly in South Africa. Moreover, HIV-1 subtype B and C integrase 
enzymes have been shown to exhibit differential patterns of resistance to integrase inhibitors 
in in vitro biochemical assays (Bar-Magen et al., 2009).  
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Since preliminary evidence suggest the possibility that HIV-1 subtypes may differ in their 
sensitivity to INSTI it is important to provide genotypic and phenotypic data on these drug 
targets in the context of the evolving HIV genetic landscape (Marconi et al., 2008; Fish et al., 
2010; Eshleman et al., 2009). Thus, this study aimed to select for ARV drug resistance in 
HIV-1 subtype C primary viruses grown in the presence of INSTIs, in order to understand 
how antiviral resistance may emerge to new drug agents as well as to direct future research 
and development of the next generation INSTIs with improved efficacy against known 
mutants (Eron et al., 2010). 
 
In vitro selection of RAL, EVG and DTG resistance using primary HIV-1 subtype C isolates 
from South Africa could yield INSTI mutation profiles specific to the region. As the 
development of resistance to RAL, EVG and DTG is likely to influence the use of those 
inhibitors in HAART regimens; resistance profiling would be instructive to the requirements 
of subsequent generations of HIV-1 IN inhibitors. The analysis of large patient resistance data 
groups will result in an improved understanding of resistance pathways in HIV-1 subtype C, 
but in vitro selection can also indicate prospective resistance pathways as mutations produced 
are likely to be similar to those observed in vivo. Moreover, in vitro selection enables the 
rapid genotyping and phenotyping of mutant viruses, and validation with site-directed 
mutants allows the description of the change in drug susceptibility due to each specific 
mutation. In this way a database comprising of the degree of susceptibility, cross resistance 
and the identification of possible compensatory mutants and other resistance-associated 
mutations to a wide range HIV-1 subtype C IN inhibitors can be built. 
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1.7. Hypothesis 
In vitro passage of WT and ARV resistant HIV-1 subtype C primary virus isolates in the 
presence of increasing concentrations of RAL, EVG and DTG could provide defined 
resistance pathways associated with HIV-1 subtype C prevalent in South Africa. 
 
1.8. Study objective 
The overall objective of this study was to establish the ARV drug resistance mutation profiles 
of HIV-1 subtype C primary virus isolates that evolve/emerge under selective pressure of the 
INSTIs RAL, EVG and DTG. This was to be accomplished through the fulfilment of the 
following aims: 
 
• To perform in vitro selection of primary HIV-1 subtype C drug resistant mutant 
viruses grown in peripheral blood mononuclear cells (PBMCs) with increasing 
concentrations of the INSTIs RAL, EVG and DTG.  
• To genotypically characterise the emergence of mutations associated with ARV drug 
resistance to RAL, EVG and DTG.  
• To determine the impact of drug resistance-associated mutations on RC/enzyme 
fitness. 
• To determine the effect of drug resistance-associated mutations on retroviral DNA 
binding. 
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CHAPTER 2: MATERIAL AND METHODS 
 
 
 
2.1. Materials and methods 
2.2. Mammalian cells and primary HIV-1 subtype C preparation 
PBMC isolation, virus expansion and tissue culture infectious dose (TDIC50) determination 
assays were carried out in accordance with standard operating procedures (SOPs) from the 
HIV Pathogenesis Research Laboratory, Department of Molecular Medicine and 
Haematology at the Faculty of Health Sciences, University of the Witwatersrand. Six primary 
HIV-1 subtype C virus isolates designated FV3, FV5, FV6, MR69, MR81 and MR89 were 
randomly selected for the INSTIs resistance study. The FV (FV3, FV5 and FV6) virus 
isolates were isolated from treatment naïve HIV/AIDS patients at the Charlotte Maxeke 
Johannesburg Academic Hospital in Johannesburg, South Africa (Connell et al., 2008). The 
MR (MR69, MR81 and MR89) virus isolates were isolated from HIV/AIDS treatment 
experienced patients, and were known to contain NNRTI/NRTI resistant mutations (as shown 
in Table 2.1 below).  
 
Table 2.1: A summary of NRTI/NNRTI resistant mutations from baseline MR virus isolates. 
HIV-1Virus Isolate NRTI Resistant mutations NNRTI Resistant mutations 
MR69 None K103N 
MR81 M184V K103N/K238N 
MR89 M184V K103N 
K103N is associated with high-level resistance to RFV and NVP; M184V is associated with high-level resistance to FTC and 3TC; K238N 
is associated with resistance to EFV and NVP (resistance information was obtained online from: http://hivdb.stanford.edu/DR/). 
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2.2.1. Isolation of PBMCs 
Buffy coats (3 pooled) were collected from the South African National Blood Service 
(SANBS), South Africa. For PBMC isolation, buffy coats were first pretreated with the 
RosetteSep® Human CD8 Depletion Cocktail (50 μl/ml) (StemCell Technologies, Canada) 
following manufacturer’s instructions. The CD8 depleted buffy coats were then mixed (1:1) 
with pre-warmed Dulbecco’s phosphate buffered saline (PBS) (Sigma-Aldrich, USA); and 
subsequently layered over Ficoll-Paque (4:3) (Amersham Biosciences, United Kingdom) 
prior to centrifugation at 360 x g for 30 minutes (no brakes and acceleration). The interphase 
PBMC layer was carefully aspirated and washed (x2) with 45ml PBS (22 °C) by centrifuging 
at 400 x g with maximum (9) brakes and acceleration, to remove platelets. PBMCs were 
resuspended to a concentration of 1.5x106 /ml in 10% growth media (89% RPMI (Sigma 
Aldrich, USA), 10% fetal bovine serum (FBS) (Highveld Biologicals PTY LTD, US) and 1% 
100x penicillin/streptomycin (Highveld Biologicals PTY LTD, USA). To stimulate the 
PBMCs, 1µg/ml phytohemagglutinin (PHA-P) (Sigma-Aldrich, USA) was added and cells 
were incubated over 72 hours in a 37 °C, 5% CO2 incubator. 
 
2.2.2. Virus expansion 
Approximately 1000 TCID50 primary HIV-1 subtype C virus (concentrations determined as 
described in section 2.2.3 below) was added to 3 ml PHA-stimulated  PBMCs (4.5 x106 cells) 
in 10% growth media (supplemented with 5% Interleukin-2 at 200 U/ml (IL-2; Roche, 
Switzerland)) and incubated as before. After 96 hours, 1.5 ml of supernatant was replaced 
with fresh 10% growth media and then incubated for a further 72 hours as before. Virus 
growth was monitored using an HIV-1 p24 assay (bioMérieux, France) according to 
manufacturer’s instructions. Briefly, a stored sample (100 µl) from the initial day of infection 
was tested against a sample from the final day of virus expansion. Approximately 25 µl 
disruption buffer was added onto 100 µl samples/controls, gently mixed and incubated for 1 
hour at 37 °C. Subsequently, the wells were aspirated and washed (x4) with PBS (300 µl) 
prior to addition of 100 µl conjugate solution (containing horseradish peroxidase labeled anti-
p24 antibody), followed by a further 1 hour incubation at 37 °C. The experimental wells were 
washed as before, followed by the addition of 100 µl tetramethylbenzidine (TMB) substrate 
and 30 minutes incubation at room temperature. A stop solution was added and the assay was 
quantified using a micro-plate reader at a wavelength of 450 nm with a 620 nm reference 
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wavelength. All supernatants containing high p24 values (>50 ng/ml) were clarified by 
centrifugation (400 x g), and transferred into RPMI supplemented with 20% FBS and aliquots 
were stored at -80 °C. 
 
2.2.3. Virus TCID50 determination 
PHA-stimulated PBMCs (1.5x106 cells/ml) were prepared and incubated at 37 °C, 5% CO2 
with humidity for 72 hours. Subsequently, 150 µl 10% growth medium was transferred to 
empty wells designated 4-3 to 4-8 (rows C to E, columns 4 to 9 on a 96 well round bottom 
plate). One aliquot of each of the 6 expanded viruses was thawed and diluted 1:12 in 10% 
growth media (supplemented with 5% IL-2) and added at 200 µl/well into empty wells 
designated 4-2 (columns 3 in rows C to E). Subsequently, serial dilutions (50 µl) were carried 
out from virus wells designated 4-2 into wells designated 4-3 until wells designated 4-8 
(column 9), and the excess 50 µl virus after wells designated 4-8 was discarded accordingly.  
The already prepared PBMCs (PHA-P stimulated) were then seeded 50 µl/well in virus 
containing wells (4-2 to 4-8), prior to incubation of the assay at 37 °C, 5% CO2 with humidity 
for 96 hours. Cells were then resuspended and approximately 125 µl of resuspended cells 
were replaced with an equal volume of fresh 10% growth media; before further 72 hours of 
incubation as before. Virus concentrations were determined using the HIV p24 (bioMérieux, 
France) following manufacturer’s instructions as before; and the TCID50 was calculated 
according to the Spearman-Karber equation (Finney, 1952).  
 
2.3. In vitro selection of INSTIs in primary HIV-1 grown in PBMC’s 
In vitro selection assays were carried out using the dose-escalation method adapted from 
protocols described previously (Kobayashi et al., 2011; Margot et al., 2012). In vitro 
selection assays were carried out using PHA-P stimulated PBMCs (2x106 cells/ml) isolated 
on day 1. Following PHA-P stimulation, PBMCs were infected with each of the six primary 
HIV-1 subtype C viruses (250 TCID50) and incubated for an hour to allow virus-cell binding. 
All in vitro selection assays were carried out in 10% growth media supplemented with 5% 
IL-2, and the increasing concentrations of RAL (NIH AIDS Reagent Program, USA), EVG 
(Selleck Chemicals, USA) and DTG (Selleck Chemicals, USA) prepared (10 mg/ml) in 
dimethyl sulfoxide (DMSO; Sigma Aldrich, USA). Virus proliferation was monitored once 
weekly using an HIV-1 p24 antigen assay (bioMérieux, France) as before. Cultures were 
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maintained twice weekly by replacing half (1.5 ml) the supernatant with fresh 10% RPMI 
media; followed by replacement of half the cultures by feeding cells with PHA-P stimulated 
donor PBMCs. All subcultures included INSTIs at appropriate concentrations. Cultures that 
exhibited low level p24 antigen were maintained at an unchanged drug concentration, while 
cultures with high p24 levels (>50 ng/ml) had two to four fold increases in drug 
concentration. All harvested supernatants were clarified by centrifugation (400 x g), made up 
to 20% FBS and stored at -80 °C for subsequent use in the genotyping assays.   
 
2.4. HIV ARV drug resistance genotyping 
The protocol used for genotyping and sequencing of the entire pol gene was adapted from 
van Baelen et al., (2009), and the primers used were obtained from Genbank using their 
designated accession numbers. 
 
2.4.1. Nucleic acid extraction 
Supernatant from all virus samples was thawed and used to extract total RNA using the 
EasyMag extraction kit (bioMérieux, France) and the NucliSens EasyMAG automated 
instrument (bioMérieux, France) following manufacturer’s instructions. Briefly, the input 
virus supernatant was 500 μl, which was mixed with appropriate volumes of lysis buffer and 
incubated at room temperature for 10 minutes. The lysed sample was subsequently 
transferred into a plastic vessel with 50 μl of silica beads, and RNA separation was carried 
out using automatic magnetic separation into 25 μl elution buffer. 
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2.4.2. Nested PCR   
Table 2.2 below summarizes all forward and reverse primers used in the nested polymerase 
chain reaction (PCR) and Sanger-based DNA sequencing reactions.  
 
Table 2.2: A summary of RT-PCR, PCR and sequencing primers used in the pol genotyping 
assays. 
Primer Sequence Alignment Function 
PR F1 5’-CCC TCA AAT CAC TCT TTG GCA ACG AC-3’ Forward primer RT-PCR 
VIF R3 5’-CTC CTG TAT GCA GAC CCC AAT ATG-3’ Reverse primer RT-PCR 
PR F3 5’-GCT CTA TTA GAT ACA GGA GCA GAT G-3’ Forward primer PCR 
VIF R5 5’-GGG ATG TGT ACT TCT GAA CTT-3’ Reverse primers PCR 
F7 5’-GTA CTG GAT GTG GGT GAT GC-3’ Forward primer Sequencing 
F8 5’-GTG GGA AAA TTG AAT TGG G-3’ Forward primer Sequencing 
PR_F2376 5’-TGG AAA CCA AAA ATG ATA GG-3’ Forward primer Sequencing 
F3771 5’-GCC ACC TGG ATT CCT GAG TG-3’ Forward primer Sequencing 
IN_F_4074 5’-CAA CCA GAT AAA AGT GAA TCA G-3’ Forward primer Sequencing 
IN_F_4540 5’-TAG CAG GAA GAT GGC CAG T-3’ Forward primer Sequencing 
RT_R_3304 5’-TGT ATG TCA TTG ACA GTC C-3’ Reverse primer Sequencing 
R1 5’-CTC CCA CTC AGG AAT CC-3’ Reverse primer Sequencing 
RT_R_4150 5’-CTT TGT GTG CTG GTA CCC ATG-3’ Reverse primer Sequencing 
IN_R_4348 5’-CTC CTT TTA GCT GAC ATT TAT CAC-3’ Reverse primer Sequencing 
VIF_R_5193 5’ATG TGT ACT TCT GAA CTT-3’ Reverse primer Sequencing 
Inseq2R 5’-CTG CCA TTT GTA CTG CTG TC-3’ Reverse primer Sequencing 
Primers used were obtained from van Baelen et al., 2009. 
 
Extracted viral RNA was used in RT-PCR to produce complementary DNA (cDNA) 
encoding the entire RT, RNAseH and IN genes (referred to as RT-IN, 2898 bp in HXB2, 
Gen-bank accession number K03455) (van Baelen et al., 2009). RT-Outer PCR was modified 
using a one-step Super-Script III RT/Platinum Taq High Fidelity (Invitrogen, USA) with 
primers PR F1 (0.2 µM) (positions 2252-2277 in HXB2) and VIF R3 (0.2 µM) (5243-5266) 
with the following thermal cycling conditions:  reverse transcription for 30 minutes at 56 °C, 
followed by outer amplification for 2 minutes at 94 °C; 30 cycles of 15 seconds at 92 °C, 30 
seconds at 62 °C and 3 minutes and 30 seconds at 68 °C; and a final elongation for 10 
minutes at 68 °C. The outer PCR was carried out with 2 µl cDNA product using the Expand 
High Fidelity Polymerase kit (Roche Diagnostics, Germany) following the manufacturer’s 
instructions. Briefly, primers used in the assay were 0.304 µM VIF R5 (5193-5213) and 
0.304 µM PR F3 (2316-2340) with the following thermal cycling conditions: 2 minutes at 94 
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°C; 35 cycles of 15 seconds at 94 °C, 30 seconds at 60 °C and 3 minutes at 68 °C; and a final 
elongation for 10 minutes at 68 °C (van Baelen et al., 2009). 
 
2.4.3. DNA purification, cycle sequencing and DNA sequencing 
Amplicons were purified using the QiaQuick PCR purification kit (Qiagen, USA) following 
the manufacturer’s instructions. Briefly, 500 µl of Buffer BP was added to 100 µl PCR 
product and the mixture was transferred onto a QIAquick spin column supported by a 2 ml 
collection tube. The samples were centrifuged at 17 900 x g for 60 seconds, and subsequently 
the flow-through was discarded. Approximately 750 µl Buffer PE was added to the column 
and the sample was centrifuged as before. To remove residual ethanol from Buffer PE an 
additional centrifugation into an empty QIAquick tube was carried out for 60 seconds, and 
subsequently the column was transferred onto a sterile collection tube. Purified DNA was 
eluted with 25 µl elution buffer in a sterile 1.5 ml micro-centrifuge tube, prior to analysis 
using 2% agarose gel analysis stained with 5 µg/ml ethidium bromide (Bio-Rad, USA) and 
visualized on a Chemidoc (Bio-Rad, USA) system.  
 
2.4.3.1. DNA sequencing and analysis 
Cycle sequencing was carried out using the BigDye Terminator cycle sequencing kit 
(including the relevant sequencing primers listed in Table 2.2) according to manufacturer’s 
instructions (Applied Biosystems, USA). The thermal cycling conditions for cycle 
sequencing were 1 minute at 96 °C; 25 cycles of 10 seconds at 96 °C, 5 seconds at 50 °C and 
4 minutes at 60 °C; and a final elongation for 10 minutes at 72 °C. The sequencing reactions 
were then cleaned as per manufacturer’s instructions. The final sequencing reactions involved 
addition of 10 µl HIDITM Formamide (Applied Biosystems, USA) and the amplicons were 
sequenced using the ABI3730xl automated sequencer overnight (Applied Biosystems, USA). 
All sequencing data was analysed using the Sequencher® version 4.8 (Gene Codes 
Corporation, USA) sequence analysis program. Nucleotide sequences were aligned in Clustal 
X 2.0 (Thompson et al., 1997), and converted to amino acids in GeneDoc 2.7 (Informer 
Technologies, USA). The nucleotide and amino acid sequence alignment was extensively 
analysed for the presence of any mutations associated with resistance to known INIs, as well 
as RTI and PI (http://hivdb.stanford.edu). 
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The INSTI mutations listed in the Stanford University: HIV Drug Resistance Database 
(http://hivdb.stanford.edu/DR/INIResiNote.html) that were relevant for each inhibitor used in 
this study were: 
 
RAL - T66A/K, L68V/I, L74M, E92Q, Q95K, T97A, F121Y, E138K/A, G140S/A/C, 
Y143C/R/H, Q148H/K/R, N155H/S, E157Q, G163R/K. 
EVG - H51Y, T66A/I/K, L68V/I, E92Q, Q95K, T97A, H114Y, F121Y, E138K/A, 
G140S/A/C, P145S, Q146P, S147G, Q148H/K/R, S153Y, N155H/S, E157Q, R263K. 
DTG - E92Q, E138K/A, G140S/A, Q148H/R/K. 
 
2.4.4. Sequencing using the Illumina MiSeq  
In order to detect minority variants or quasispecies, an aliquot of the DNA amplicons 
obtained in section 2.4.2 were also sequenced on the MiSeq instrument (Illumina, USA). The 
DNA was quantified using the Qubit® dsDNA BR quantification kit and a Qubit® 2.0 
fluorimeter (Life Technologies, USA). Libraries were prepared using the Nextera® XT DNA 
sample preparation kit in accordance with manufacturer’s instructions (Illumina Nextera® XT 
DNA sample preparation guide, 2012). Briefly, Tagment DNA buffer was transferred into the 
Nextera XT tagment amplicon plate (NTA; Illumina, USA) at 10 µl/well; and 5 µl input 
DNA was subsequently added at 0.2 ng/ul (per well) and mixed gently. Amplicon tagment 
mix (Illumina, USA) was subsequently added at 5 µl/well and mixed as before. The NTA 
plate was sealed and centrifuged (280 x g at 20 °C for 1 minute), and subsequently incubated 
(55 °C for 5 minutes, hold at 10 °C) in a thermal cycler. Neutralize Tagment buffer (Illumina, 
USA) was subsequently added 5 µl/ sample and were mixed gently, and then centrifuged as 
before. The NTA plate was incubated at room temperature for 5 minutes, and subsequently 
1µl of sample was assessed for tagmentation using the HS bioanalyzer chip (Illumina, USA). 
For PCR amplifications, a 15 µl/well Nextera PCR master mix (Illumina, USA) was added to 
each column on the experimental NTA plate, followed by 5 µl/well (to each row) of index 
primers (i7 and i5) and mixed gently. The experimental NTA plate was then sealed and 
centrifuged as before. The plate was subsequently placed in a thermocycler and PCR was 
carried out under the following conditions: 72 °C for 3 minutes, 95 °C for 30 seconds, 12 
cycles of: (95 °C for 10 seconds, 55 °C for 30 seconds, 72 °C for 30 seconds), 72 °C for 5 
minutes, and a final hold at 10 °C.  
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A PCR clean-up was carried by centrifugation (280 x g for 1 minute at 20 °C), and 
subsequently the PCR product was transferred at 50 µl/well into a Clean amplified plate 
(CAA; Illumina, USA). AMPure XP beads were vortexed and added (30 µl/well), mixed and 
then incubated at room temperature for 5 minutes. The experimental CAA plate was then 
placed on a magnetic stand and beads were washed (x2) with 200 µl of 80% ethanol before 
air drying on the bench for 15 minutes. Resuspension buffer was added at 52.5 µl/well, mixed 
and incubated for 2 minutes at room temperature. The CAA plate was placed back onto a 
magnetic stand for another 2 minutes, and subsequently 50 µl of supernatant was transferred 
onto a sterile Clean amplified NTA plate (CAN). Thereafter, 20 µl of the supernatant was 
transferred into a MIDI 96-well Library normalisation plate (LNP; Illumina, USA), prior to 
addition of the Library normalisation additives (LNA1; Illumina, USA)/Library normalisation 
beads (LNB1; Illumina, USA) mix (45 µl/well). The LNP plate was then kept on a microplate 
shaker at 1800 rpm for 30 minutes before it was positioned onto a magnetic stand for 2 
minutes/until the supernatant was clear. Subsequently the supernatant was gently removed 
and discarded; and the wells were washed (x2) using Library normalisation wash 1 (45 µl; 
with shaking at 1800 rpm for 5 minutes; and magnetic stand as before). A 30 µl 0.1 N NaOH 
solution was added to the beads to elute the sample and incubated at room temperature (with 
shaking 1800 rpm for 5 minutes). An internal control was prepared by thoroughly mixing 
(vortexed and centrifuged at 280 × g for 1 minute) 5 µl of 4 nM PhiX library with 5 µl of 0.2 
M NaOH and incubated (denatures the PhiX library) at room temperature for 5 minutes. The 
PhiX library (10 μl) was added to a pre-chilled HT1 (990 μl).  Subsequently, a Library 
normalisation storage buffer was added at 30 µl to the samples which were sealed and 
centrifuged to 112 x g for 1 minute before the all samples were pooled (including the control 
PhiX library) and diluted with 571 µl Hybridization buffer (Illumina, USA) and loaded onto a 
Miseq reagent cartridge kit version 2 (Illumina, USA), subjected to pair end 2×250 base-pair 
reads (maximum output of 7.5) and sequenced according to the Miseq System User Guide 
(part # 15027617). 
 
2.5. In silico analysis of the major in vitro selected mutations 
A three-dimensional docking model of the HIV-1 IN catalytic core domain was prepared 
based on PDB entry 1QS4 (Goldgur et al., 1999) as a starting point (Accelrys Discovery 
Studio Version 3.5). This structure includes three identical chains of the HIV-1 IN catalytic 
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core, determined at a resolution of 2.1 Å. All water molecules as well as chains B and C were 
removed and an unresolved loop region (residues 141 – 144) was built onto the existing chain 
A. The second magnesium ion was placed in the active site based on the closely related two-
metal active site of Tn5 transposase (PDB entry 1MM8). The protein structure of the 
monomeric catalytic core domain was prepared using the Protein Preparation tool in Accelrys 
Discovery Studio, and all hydrogen atoms were added. The protonation state and side-chain 
orientation of all residues were optimised for hydrogen bonding. The molecule was typed 
with the CHARMm forcefield and minimised using the smart minimiser protocol in DS4.0 
with a maximum of 5000 steps to an energy change of 0.0 kJ. Quality indication of the 
protein model was verified using Ramachandran plots, verify modeller and verify score. Point 
mutations were manually introduced to reflect experimental results and literature reports. 
 
2.6. Mutant and WT enzyme generation 
 Attempts were made to expand the viral isolates that harboured antiretroviral drug resistance 
mutations in PBMCs, but very low p24 antigen levels were routinely obtained following 
storage at -80 °C. This was indicative of some replicative fitness cost associated with these 
mutations. Thus, the decision was made to express, purify and characterize recombinant IN 
harbouring the relevant mutations.   
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2.6.1. Site-directed mutagenesis, plasmid preparation and sequencing 
A pET-15b vector (Novagen, Germany) which encodes the full-length FV6WT integrase gene 
(HIV-1 subtype C 05ZAFV6) (Fish et al., 2010) was available for use in this study. The 
FV6WT recombinant plasmid was used as a template to introduce relevant mutations 
identified in sections 2.4.3.1 above. Table 2.3 below summarizes all forward and reverse 
primers used in site-directed mutagenesis assays for induction of the HIV-1 IN mutants. 
 
Table 2.3: Primers used in site-directed mutagenesis of the integrase gene.  
Mutation Sequence Alignment TM* 
N155H 5’-GAGTAGTAGAATCTATGCATAAAGAATTAAAG-3’ Forward primer 60.81 
5’-CTTTAATTCTTTATGCATAGATTCTACTACTC-3’ Reverse primer 
T66I 5’-GCAATTAGATTGTATACATTTAGAAGGAAAAG-3’ Forward primer 60.81 
5’-CTTTTCCTTCTAAATGTATACAATCTAATTGC-3’ Reverse primers 
Q148R 5’-AATCCCCAAAGTCGGGGAGTAGTAGAATC-3’ Forward primer 67.45 
5’-GATTCTACTACTCCCCGACTTTGGGGATT-3’ Reverse primer 
F121Y 5’-GATAATGGCAGTAATTACACCAGTGCTGCAG-3’ Forward primer 67.29 
5’-CTGCAGCACTGGTGTAATTACTGCCATTATC-3’ Reverse primers 
R263K 5’-CATAAAAGTAGTACCAAGAAAGAAAGCAAAAATC-3’ Forward primer 62.25 
5’-GATTTTTGCTTTCTTTCTTGGTACTACTTTTATG-3’ Reverse primer 
E92Q 5’-CAGAAGTTATCCCAGCACAAACAGGACAAGAAAC-3’ Forward primer 68.28 
5’-GTTTCTTGTCCTGTTTGTGCTGGGATAACTTCTG-3’ Reverse primers 
H114L 5’-GGCCAGTCAAAGTAATACTTACAGATAATGGCAG-3’ Forward primer 67.34     
5’-CTGCCATTATCTGTAAGTATTACTTTGACTGGCC-3’ Reverse primers 
- Desired mutation; *TM- melting temperature 
 
Mutagenesis was carried out using the QuikChange Lightning Site-Directed Mutagenesis kit 
according to manufacturer’s instructions (Agilent Technologies, USA). Briefly, sample 
reactions were set up using 5 μl of 10× reaction buffer, 1 μl (100 ng) of double-stranded (ds) 
DNA template, 1.25 μl (125 ng) of each reverse and forward primer (shown in Table 2.3), 1 
μl of dNTP mix, 1.5 μl of QuickSolution reagent, 39 μl of high purity water and then 1 μl of 
QuickChange® Lightning enzyme was added. The reactions were thermocycled using the 
following conditions: 2 minutes at 95 °C, 18 cycles of 20 seconds at 95 °C, 10 seconds at 
primer melting temperature 60 °C (dependent on GC content, Table 2.3), 30 seconds at 68 
°C; and a final elongation for 5 minutes at 68 °C. Subsequently, 2 μl of DpnI restriction 
enzyme (Agilent Technologies, USA) was added directly to each reaction, mixed, spun down 
and incubated at 37 °C for 5 minutes to digest the parental dsDNA. 
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Plasmids containing mutated cDNA sequences were then transformed into StellarTM 
competent Escherichia (E.) coli cells (Clontech Laboratories, USA). Briefly, 50 µl of the 
competent bacterial cells were gently mixed with 5µl of site-directed mutagenesis DNA 
product (1-100 ng) and incubated on ice for 30 minutes in a sterile Eppendorf tube. 
Subsequently the cells were heat shocked at 42 °C for exactly 30 seconds, and thereafter 
incubated again on ice for 2 minutes. Approximately 250 µl of pre-warmed (37 °C) SOC 
media (without antibiotics) (Clontech Laboratories, USA) was added to the competent cells, 
followed by 1 hour of incubation at 37 °C with shaking (250 rpm). The transformed cells (20 
µl) were then incubated overnight (12-16 hours) at 37 °C on Luria Bertani (LB) agar 
(Laboratorios Conda, Spain) plates supplemented with  100 µg/ml ampicillin (Melford 
Laboratories Ltd, UK). Subsequently, one colony was inoculated into LB Broth (Laboratorios 
Conda, Spain) supplemented with 100 µg/ml ampicillin and incubated for another 12-16 
hours with shaking at 250 rpm. 
 
Plasmid DNA purification was carried out using a kit (Machenery-Nagel GmbH & Co. KG, 
Germany) according to manufacturer’s instructions. Briefly, 400 ml transformed bacterial 
cells were cultivated and harvested by centrifugation at 11000 x g for 30 seconds. The 
bacterial cells were lysed by resuspension of the pellet in 250 µl suspension buffer, followed 
by addition of 250 µl lysis buffer. The lysate was incubated for 5 minutes at room 
temperature before 300 µl of neutralization buffer was added. The lysate was clarified using 
centrifugation at 11000 x g for 10 minutes, and the supernatant was loaded onto a 
NucleoSpin® Plasmid column supported by a collection tube. The DNA was bound onto the 
column by centrifugation at 11000 x g for 1 minute and flow through was discarded, before a 
wash with 500 µl buffer AW followed by a wash with 600 µl buffer A4 (supplemented with 
80%  ethanol) at 11000 x g for 1 minute each. The dry silica membrane binding desired DNA 
was air dried at 11000 x g for 2 minutes, prior to elution (50µl elution buffer) by 
centrifugation at 11000 x g for 1 minute. Plasmid DNA was quantified using the NanoDrop 
2000 spectrophotometer (Thermo Scientific, USA) at a wavelength of 260 nm, and a known 
concentration of each mutated plasmid was sequenced using the Universal T7 promoter and 
the T7 terminator primers at Inqaba Biotech, South Africa. 
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2.6.2. Recombinant protein expression  
Competent E.coli BL21 (DE3) pLyS cells (Lucigen, USA) were transformed using the 
extracted recombinant plasmids as before (refer to section 2.5.1).  The transformed cells (20 
µl) were then incubated overnight (12-16 hours) at 37°C °C on LB agar (Laboratorios Conda, 
Spain) plates supplemented with  antibiotic (100 ug/ml ampicillin and 100ug/ml 
chloramphenicol; Sigma Aldrich, USA). Overnight recombinant E. coli BL21 (DE3) cultures 
of wild-type and INSTI mutants were each diluted 100x into 400 ml LB broth (supplemented 
with 100 µg/ml ampicillin) and grown to log phase (OD reading: 0.4 - 0.6 at a 600 nm 
wavelength) by incubation at 37 °C for 2-3 hours with shaking (250 rpm). Subsequently, the 
IN overexpression was induced by addition of 400 µl of 1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) (Sigma Aldrich, USA), and the bacterial cultures were 
incubated as before for 3 hours. Bacterial cultures were then centrifuged at 1200 x g for 20 
minutes at 4 °C; supernatant was discarded and pellets were stored at -20 °C overnight. 
Samples from before over-expression and samples obtained following over-expression were 
ran on the Mini-Protean® TGX Stain-Free™ Precast Gels (Bio-Rad, USA) and visualized on 
the ChemiDoc MP System (Bio-Rad, USA). 
 
2.6.3. Nickel-chelating column chromatography  
Purification of all the recombinant wild-type and mutant IN proteins was carried out using 
Nickel Chelating Column Chromatography. The nickel-bound resin (Macherey Nagel, 
Germany) was recharged with 2.5 ml of 0.1 M NiSO4 (Sigma Aldrich, USA) and equilibrated 
with 10 column volumes of binding buffer (20 mM HEPES  (pH 7.2; Sigma Aldrich, USA), 1 
M NaCl (Sigma Aldrich, USA), 5 mM Imidazole (Sigma Aldrich, USA), 10% glycerol 
(Melford, UK), 0.05% Igepal (Sigma Aldrich, USA)) on the Acta Prime plus (GE Healthcare, 
UK). The frozen BL21 (pLys) pellets were resuspended in 50 ml lysis buffer (20 mM HEPES 
(pH 7.2), 1 M NaCl, 5 mM Imidazole, 10 mM MgCl2 (Sigma Aldrich, USA), 0.25% CHAPS, 
1 mM phenylmethylsulfonylfluoride (PMSF; Sigma Aldrich, USA) and 10 ul DNase 1 
(Sigma Aldrich, USA)), homogenised and incubated on ice for 30 minutes with gentle 
stirring. The Labsonic® M sonicator (Sartorius Stedim, Germany) was used (75% at 0.6 
cycles) to disrupt cells (1 minute/sonication). The bacterial lysate was subjected to 
centrifugations at 15000 x g at 4 °C for 30 minutes, and supernatant was pooled into 50 ml 
tubes. The 50 ml supernatant was then loaded onto the super loop (washed with 50 ml 
binding buffer) and bound at a 1 ml/minute flow-rate with a 0.3 MPa maximum pressure. 
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Subsequently, the bound protein was washed with 5 column volumes of binding buffer, then 
washed with 10 column volumes of wash buffer 1 (20 mM HEPES (pH 7.2), 1 M NaCl, 60 
mM Imidazole, 10% glycerol, 0.05% Igepal) followed by 10 column volumes of wash buffer 
2 (20 mM HEPES (pH 7.2), 1 M NaCl, 150 mM Imidazole, 10% glycerol, 0.05% Igepal). 
 
A gradient of 75 ml at 100% elution buffer (20 mM HEPES (pH 7.2), 1 M NaCl, 600 mM 
Imidazole, 10% glycerol, 0.05% Igepal) final was then set; with 3 ml fraction sizes. Collected 
fractions were concentrated using ultrafiltration membrane (10 000 Dalton, Dia: 44.5 mm, 
cellulose) (Millipore, USA) under nitrogen pressure. An equilibrated PD-10 column (GE 
Healthcare, UK) was used for buffer exchange in which the IN concentrate was transferred 
into 25 ml storage buffer (20 mM HEPES (pH 7.5), 1 M NaCl, 0.1 mM EDTA, 1 mM DTT  
(Melford, UK), 10% Glycerol). The collected flow-through was measured for protein on the 
NanoDrop at a wavelength of 280 nm and Beer-Lambert law was used to calculate the IN 
concentration.. Purified IN was aliquoted, snap-frozen in liquid nitrogen and stored in -70 °C.  
 
2.7. Polyacrylamide gel electrophoresis (PAGE) and Western-blot analysis 
The HIV-1 IN protein was verified using PAGE and Western-blot analysis. Briefly, 4-15% 
tris-glycine precast stain-free gels (Bio-Rad, USA) were used and the target IN enzyme was 
identified at 32 kDa using the ChemiDoc MP system (Bio-Rad, USA). The gels were then 
incubated in gel transfer buffer (20% methanol, 80% high purity water) for fifteen minutes. 
An iBlot gel transfer stack (Life Technologies, USA) was used to transfer protein onto a 
polyvinylidene difluoride (PVDF; Life Technologies, USA) membrane in accordance with 
manufacturer’s instructions. An automated Western-blot assay was carried out using the 
Benchpro 4100 (Life Technologies, USA). Briefly, the PVDF membrane was incubated in 
blocking buffer (420 mM Tris pH 7.6, 137 mM NaCl, 5% BSA and 0.1% Tween 20), and 
subsequently washed in Tris Buffered Saline with Tween® 20 (TBST-1x) (420 mM Tris pH 
7.6, 137 mM NaCl, 0.1% Tween 20) prior to incubation with anti-His.H8 (Abcam, UK) 
primary antibodies) (1:1000) for  ninety minutes. The membrane was washed again as before, 
and subsequently incubated for an hour with secondary rabbit anti-mouse horseradish 
peroxidase linked IgG secondary antibody (1:2000; KPL, USA). HIV-1 IN detection was 
carried out on the ChemiDoc using the Supersignal West Pico Chemiluminescent substrate 
(Thermo Fisher Scientific, USA) following manufacturer’s instructions. 
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2.8. HIV-1 strand transfer assay 
The direct HIV-1 IN strand transfer assay was adapted from Mphahlele et al., 2012, and 
carried out to determine the strand transfer capacity of HIV-1 subtype C mutants with respect 
to the WT HIV-1 subtype C enzyme. Donor (d) DNA (150 nM; biotin 5’-
ACCCTTTTAGTCAGTGTGGAAAATCTCTAGCA-3’/ 5’- 
ACTGCTAGAGATTTTCCACACTGACTAAAAG-3’; Inqaba Biotech Pretoria, South 
Africa) was prepared in Tris-buffer-A (10 mM Tris-HCl, 0.1 M NaCl; pH 7.2) and 
transferred into streptavidin coated microplate (MP) at 100 µl/well and subsequently 
incubated at 25 °C (with shaking 50 rpm) for an hour. Therefter, the wells were washed with 
working solution of PBS (250 μl). HIV-1 IN (2 µM) enzyme was prepared in reaction-buffer 
(20 mM HEPES, 30 mM NaCl, 10 mM MgCl2, 10 mM MnCl2, 0.05% Igepal; pH 7.5) 
(Chow, 1997) and transferred to 100 µl/well; the assay was then incubated for thirty minutes 
as before. Subsequently, the wells were washed twice with 250 µl reaction buffer, and 
approximately 90 µl reaction buffer was added to wells prior to a thirty minute incubation at 
37 °C. About 2.5 μM target DNA (5’-TGACCAAGGGCTAATTCACT-3’ Fluorescein and 
5’-AGTGAATTAGCCCTTGGTCA-3’ Fluorescein; Inqaba Biotech, Pretoria, South Africa) 
was prepared in reaction buffer and added to assay 10 µl/well; and the assay was incubated 
for an hour at 37 °C. The assay was then washed with 250 µl working solution of saline-
sodium citrate (SSC) buffer (0.03 M sodium citrate, 0.3 M NaCl; pH 7.0), and subsequently 
monoclonal anti-FITC alkaline phosphatase (1:10 000) (Sigma Aldrich, USA) prepared in 
Tris-buffer-B (50 mM Tris-HCl, 150 mM NaCl, 0.05% Tween 20; pH 7.4) was added 200 
µl/well. The assay was incubated for two hours at 25 °C and subsequently washed with Tris-
buffer-B (without 0.05% Tween 20). A FirePhosTM Microwell Phosphate substrate system 
was prepared in accordance with manufacturer’s instructions (KPL, USA) and added 100 
µl/well. The assay was then incubated for thirty minutes at 37 °C, stopped and quantified at a 
wavelength of 505 nm on the xMARKTM (Bio-Rad, USA). 
Although IN function in a multimeric form is stabilized by zinc, it was not included in the 
assay reagents described above due to the fact that the use of the metal co-factor manganese 
has been shown to be adequate (Lee and Han, 1996).  
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2.9. Binding kinetic analysis of W/T and mutant IN DNA and INSTI binding  
The kinetics of the unlabelled pre-processed (3’-end artificially cleaved) dDNA binding to 
the HIV-1 subtype C IN mutants were tested with reference to the WT subtype C IN enzyme 
using surface plasmon resonance (SPR). All SPR experiments were carried out using the 
ProteOnTM XPR36-Protein Interaction Array System (Bio-Rad, USA) at 25 °C. For direct IN-
DNA binding kinetics, an HTG (a nitriloacetic acid (NTA)-linked) chip (Bio-Rad, USA) was 
preconditioned using 0.5% SDS, 50 mM NaOH, 100 mM HCl and 0.3 M EDTA (pH 8.5) and 
subsequently the HTG chip was charged with 0.5 M NiSO4. The WT and WT- IN mutants 
were prepared (0.6 mg/ml) in Tris buffer (50 mM Tris, 150 mM  NaCl, 10 mM MgCl2, 1 mM  
MnCl2 and 0.005% Tween 20; pH 7.6) and immobilized on separate flow cells within the 
same sensor HTG chip (5 proteins immobilised per kinetic experiment) using a flow rate of  
25 µl/min to a final response unit (RU) of between 250 and 4560 (final RU reached: IN-W/T 
1300 RU, N155H 4560 RU, T66I 1944 RU, Q148R 630 RU, R263K 1100 RU, F121Y 
250RU,  H114L 1300 RU and E92Q 720 RU). The RU signal was calculated as the 
difference between immobilised protein and the corresponding NiSO4 channel surface. 
Protein immobilization using HTG occurs through bio-molecular interactions that involve 
binding of the IN-histidine tag to the nickel (II) sulphate surface. IN-dDNA interactions were 
initiated by flowing (100 µl/min) dDNA at concentrations of 10 µM, 5 µM, 2.5 µM, 1.25 
µM, 0.625 µM for T66I, N155H and R263K and 5 µM, 2.5  µM, 1.25 µM, 0.625 µM and 
0.31255 µM for W/T, E92Q, H114L, F121Y and Q148R.  Buffer injections and control 
surface (0.5 M NiSO4 only surface) interactions were subtracted for all data in all binding 
experiments. All data was fitted to a Langmuir 1:1 binding algorithm using the ProteOn 
Manager Software (Version 3.1.0.6; Bio-Rad, USA). 
 
2.10. Statistical analysis 
The GraphPad software QuickCalcs (GraphPad Software Inc, USA) - t test calculator 
(available online at: http://graphpad.com/quickcalcs/ttest1.cfm?Format=SD) was used to 
determine the p-values for the HIV-1 subtype C mutant strand transfer capacity results.  
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CHAPTER 3: RESULTS  
 
 
3.1. In vitro selection and virus break-through 
All six selected primary HIV-1 subtype C isolates were successfully expanded in PHA-
stimulated PBMCs, their TCID50 established, and appropriate concentrations used in the 
subsequent in vitro selection assays. The in vitro selection assays were carried out using a 
dose-escalation method in the presence of RAL, EVG and DTG, and drug concentrations 
were gradually increased depending on viral proliferation, which was monitored using an 
HIV-1 p24 antigen assay. Subjecting HIV-1 to increasing INSTI drug concentrations often 
led to pressure on viral replication (decrease in p24 antigen detected), and drug 
concentrations were maintained until there was recovery of viral proliferation. For example, 
for a period of 16 days a reduction in p24 levels was observed with virus isolates MR69 
(Figure 3.1A) and FV6 (Figure 3.1B) under EVG pressure; and subsequent recovery in p24 
levels from day 56 onwards. A similar reduction in HIV-1 subtype C levels under RAL 
pressure was observed from day 32 (Figure 3.1A) and 48 (Figure 3.1B) with MR69 and FV6, 
respectively.  
 
 
Figure 3.1: Graphical representation of the HIV-1 subtype C MR (A) and FV (B) viruses during in vitro 
selection and virus break-through. Virus break-through during selection was defined through a reduction 
followed by an increase of HIV-1 p24 antigen levels in the culture supernatant over a period of time.  
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Increases in INSTI drug concentrations were adjusted appropriately to permit the emergence 
of resistant variants. The FV and MR viruses replicated equally well in the presence of 
increasing concentration of RAL, but the presence of pre-existing NRTI and/or NNRTI 
mutations (in the 3 MR viruses) appeared to delay the INSTI dose-escalation for EVG and 
DTG (Figure 3.2).   
  
 
Figure 3.2: Dose-escalation curves for the in vitro selection studies with RAL, EVG and DTG in the HIV-1 
subtype C FV (antiretroviral drug naïve) and MR (reverse transcriptase inhibitor resistant).  
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3.2. Genotyping 
3.2.1. Sanger-based sequencing 
The acquisition of INSTI mutations by primary HIV-1 subtype C isolates during the in vitro 
selection studies with RAL, EVG and DTG was confirmed by population-based sequencing 
with baseline HIV-1 isolates as reference (Table 3.1). A summary of the major primary 
INSTI resistance mutations, major accessory mutations and rare primary INSTI resistance 
mutations is presented in Table 3.2.   
Under RAL pressure, the primary virus isolates FV6, MR69 and MR89 developed the major 
drug resistance mutations Q148R, N155H and N155H, respectively (Table 3.2). In vitro 
selection with EVG induced major INSTI resistance mutations T66I, T66I and T66K in virus 
isolates in FV6, MR69 and MR81, respectively. In addition, the rare primary INSTI-
resistance mutation F121Y and the major INSTI accessory mutation R263K emerged with 
EVG pressure in FV3 and FV6, respectively (Table 3.2). Drug resistance-associated mutation 
E92Q emerged under DTG pressure as a primary mutation in virus isolate FV3 (Table 3.2), in 
combination with mutations V31LV/A38AP/T93K/D116N/S119C/K136Q. Additionally, the 
rare primary drug resistance-associated mutation M50I was selected in virus isolate MR81 
(Table 3.2). Naturally occurring polymorphisms believed to be associated with DTG 
resistance at positions 101, 124 and 201, were observed from baseline primary HIV-1 
subtype C in all virus isolates.  
The pre-existing reverse transcriptase mutations in virus isolates MR69, MR81 and MR89 
remained unchanged during culture.  
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Table 3.1: Baseline IN sequences of primary HIV-1 isolates selected. 
HIV-1 subtype C isolates Sequences 
FV3 D25E, L101I, T112V, T124A, T125A, K136Q, Q177L, 
V201I, T218I, L234I, A265V, R269K, D278A, S283G 
FV5 K7R, E11D, D25E, F100Q, L101I, K111T, T112V, T124A, 
T125A, K136Q, D167E, V201I, K215N, L234I, D278A, 
R284G, D286N 
FV6 D25E, V31I, M50T, I72V, F100Y, L101I, T112V, T124A, 
T125A, K136Q, V201I, T218I, L234I, R269K, D278A, 
S283G, R284G, D286N 
MR69 S17N, D25E,V31I, M50T, I72V, Y99X, F100Y, L101I, 
T122V, T124A, T125A, K136Q, D167E, V201I, T218I, 
Q221S, L234I, D278A, S283G 
MR81 D25E,V31I, M50T, F100Y, L101I, T122V, T124A, T125A, 
K136Q, V201I, T218I, L234I, D278A, S283G 
MR89 S17N, D25E,V31I, M50I, I84M, L101I, T122V, T124A, 
T125A, K136Q, V201I, T218I, L234I, A265V, R269K, 
M275V, D278A, S283G 
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Table 3.2: Major antiretroviral drug resistance mutations that emerged in the HIV-1 subtype 
C primary virus isolates during in vitro selection cultures with increasing concentrations of 
RAL, EVG and DTG. The major mutations are highlighted in bold red.   
 
Integrase Inhibitor 
Virus isolate 
RAL EVG DTG 
FV3 Baseline No DRM¥ 
 Passage (P) 
sequenced  
No DRM (P44) INSTI: F121Y* 
(P44) 
INSTI: E92Q 
(P44) 
     
FV5 Baseline No DRM 
 Passage 
sequenced 
INSTI: No 
DRM (P44)  
INSTI: No 
DRM (P44) 
INSTI: No 
DRM (P39) 
     
FV6 Baseline No DRM 
 Passage 
sequenced 
INSTI: Q148R 
(P44) 
INSTI: T66I, 
R263K** (P44) 
INSTI: ND*** 
     
MR69 Baseline NNRTI: K103N 
 Passage 
sequenced 
NNRTI: K103N  
INSTI: N155H,  
H114L (P39) 
NNRTI: K103N  
INSTI: T66I 
(P44)  
NNRTI: 
K103N 
INSTI: ND 
     
MR81 Baseline NRTI: M184V 
NNRTI: K103N, K238N 
 Passage 
sequenced 
NRTI: M184V 
NNRTI: 
K103N, K238N 
INSTI: ND 
NRTI: M184V 
NNRTI: K103N, 
K238N 
INSTI: T66K 
(P44) 
NRTI: M184V 
NNRTI: 
K103N, K238N 
INSTI: M50I# 
     
MR89 Baseline NRTI: M184V 
NNRTI: K103N 
 Passage 
sequenced 
NRTI: M184V 
NNRTI: K103N 
INSTI: 
N155H/M50I 
(P44) 
NRTI: M184V 
NNRTI: K103N 
INSTI: ND 
NRTI: M184V 
NNRTI: 
K103N 
INSTI: ND 
¥DRM, drug resistance mutations; *F121Y is a rare primary INI-resistance mutation; **R263K is a major INSTI 
accessory mutation; # M50I is an accessory mutation; ***ND, Not Done, no amplification attributed to low p24 
antigen levels in culture supernatant. K103N-is a major NNRTI resistance mutation; M184V-is a major NRTI 
resistance mutation; K238N-is an accessory mutation associated with NNRTI/NRTI resistance. 
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3.2.2. High through-put sequencing: Illumina MiSeq 
High through-put sequencing results of the longitudinal culture samples allowed us to track 
the dynamic evolution of the quasispecies in response to the drug selection pressure. 
Quasispecies that were present at ≥1% of the variants were included in the analyses, and the 
prevalence of each mutation (in percentages) is shown in Figure 3.3 and Tables 3.3 to 3.5.   
 
Viruses FV3 and FV5 adapted to grow in the presence of up to 266.32 nM of RAL without 
the emergence of INI drug resistance mutations (Table 3.3). The FV6 virus introduced a 
mutation at position 148 (Q148R) which was detected at 1% of the quasispecies population as 
early as P15 (4.16 nM RAL), and was the predominant population (97%) by P33 (33.28 nM). 
Similarly, the N155H/H114L and N155H mutations emerged in viruses MR69 and MR89 
respectively. Q148R and N155H confer major resistance to RAL.  
 
Under EVG pressure, all six viruses developed INI drug resistance mutations at varying 
proportions (Table 3.4). F121Y was detected in FV3, whereas T66I/K was detected in FV3, 
FV6, MR81 and MR89 as the predominant quasispecies by the end of the study. 
Additionally, the major accessory mutation R263K emerged (22% at P39) in FV6. Q148K 
was detected at 31% of the total viral population by passage 27. F121Y, T66I/K and Q148K 
confer high level resistance to EVG.          
 
No major INI resistance mutations were detected in proportions greater that 20% in the viral 
cultures grown in the presence of DTG (Table 3.5). The V151L mutation was detected in 
FV3 (16% at P39), and is associated with low-level resistance to DTG. The G163K mutation 
was present in MR69 at proportions of 17%, but does not alter the susceptibility of HIV-1 to 
DTG. Low proportions of mutations were detected in MR81, with G140A (7%, which 
confers potential low level resistance to DTG), P145S (8%, virus is susceptible to DTG, but 
confers high level resistance to EVG) and Q148K (9%, low level resistance to DTG, but high 
level resistance to EVG and RAL).  
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Figure 3.3: The in vitro selection process showing dose-escalation concentrations of RAL (A) and EVG (B) in 
PBMCs infected with primary virus isolates FV6 and MR69. The resulting INSTI mutations found in the 
depicted virus during the passages are shown in the matched colour boxes. Points highlighted in red represent 
the passages that were sequenced. 
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Table 3.3: Resistance mutations as selected by RAL and identified using NexGen sequencing. 
T66I L74I L74M E92V Q95K T97A E138K Y143H Y143K Y143R Y143S Q146P S147G Q148H Q148K Q148R V151A V151L S153F S153Y N155H N155S E157Q G163R S230R
FV3 RAL P24 1 1
FV6 RAL P15 1 2 1 1
FV6 RAL P24 5 1 3 1
FV6 RAL P33 2 97 1
FV6 RAL P38 99
FV6 RAL P44 1 4 99
MR69 RAL P14 1 1 1 2
MR69 RAL P24 1 4 1 96 1 1
MR69 RAL P31 1 1 98 1
MR69 RAL P32 2 1 97 1
MR69 RAL P39 1 3 1 1 99 2 1
MR69 RAL P44 1 1 5 1 1 1 1 1 1 1 95 1
MR81 RAL P13 3 12 2 2 1 1 1 1 1 3 1 2 1 1 2
MR81 RAL P17 2 1 1 2 1
MR81 RAL P27 1 60 13
MR81 RAL P39 1
MR81 RAL P44 1 3 1 1 1 1 2 1 1
MR81 RAL P44 5 2 1 1 7 6 1 1 3
MR89 RAL P16 1 1 1 1 1 1
MR89 RAL P17 1 1 1
MR89 RAL P41 2 1 1 1 3 3 1 97  
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Table 3.4: Resistance mutations as selected by EVG and identified using NexGen 
sequencing. 
H51Y T66A T66I L74I L74M E92G E92Q E92V Q95K T97A G118R F121Y E138K G140C G140S
FV3 EVG P14 25
FV3 EVG P33 99
FV3 EVG P44 100
FV5 EVG P18 1 1 1
FV5 EVG P27 2 1 3 3
FV6 EVG P17 1 92
FV6 EVG P33 99 1 2
FV6 EVG P36 98 1 3
FV6 EVG P39 97 1 2 1
MR 69 EVG P14 14 1
MR 69 EVG P24 99 6
MR 69 EVG P24 98
MR69 EVG P44 98 1 1 3 1
MR 89 EVG P25 45
MR 89 EVG P29 91 1 4 5
MR89 EVG P29 93 3 1 5
Y143CY143KY143RY143SP145S Q148HQ148KQ148RV151LS153Y N155S N155T E157Q G163R S230R R263K
FV3 EVG P14 1 1
FV3 EVG P33 1 1
FV3 EVG P44 1 1
FV5 EVG P18 1 2 3 3 2 1 2 2 1
FV5 EVG P27 31 1
FV6 EVG P17 1 1 1
FV6 EVG P33 1 4
FV6 EVG P36 1 1 1 1 2 1 3
FV6 EVG P39 1 2 3 1 22
MR 69 EVG P14 12 1 1 3
MR 69 EVG P24 2 1
MR 69 EVG P24 3 1 1 1 1 2 0
MR69 EVG P44 1 1 1 2 1
MR 89 EVG P25 1
MR 89 EVG P29 1 1 1 1 4 1 3 2
MR89 EVG P29 1 1 1 2 5 3
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Table 3.5: Resistance mutations as selected by DTG and identified using NexGen sequencing. 
T66A L74I L74M F121Y E138K G140A Y143R P145S Q146P Q148H Q148K Q148R V151L S153Y N155S E157Q G163K G163R R263K
FV3 DTG P17 1 1 1 1 1 1 1
FV3 DTG P31 1 1
FV3 DTG P33 1 1 1
FV3 DTG P39 1 1 1 1 16
FV5 DTG P26 1 1
FV5 DTG P39 1 1 1
FV6 DTG P26 3 3
FV26 DTG P26
MR69 DTG P23 2 17
MR69 DTG P26 1 1 1
MR81 DTG P26 1 7 8 1 9 1 1  
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3.3. In silico analysis of mutations using Accelrys  
The position of the four major primary mutations (T66I, E92Q, Q148R and N155H), the 
major accessory mutation R263K and miscellaneous INI-associated mutation (H114L) 
selected studies were mapped using Accelrys Discovery Studio 3.5. Figure 3.4 shows a three-
dimensional docking model of the HIV-1 IN catalytic core domain prepared using PDB entry 
1QS4 as a starting point, showing the catalytic triad residues (D64, D116 and E152) in green 
and the two magnesium ions as purple spheres. Primary amino acid mutations (T66I, E92Q, 
Q148R and N155H) in the linear sequence of the wild-type protein shown in orange. 
 
 
 
 
 
Figure 3.4: A three-dimensional docking model showing the positions at which the integrase inhibitor selected 
substitutions T66I, E92Q, H114L, F121Y, Q148R and N155H within the HIV-1 integrase catalytic core domain 
occur. 
 
Figure 3.5 shows the changes in each amino acid substitution. For instance, T66I shows WT 
amino acid threonine (T66) with a hydrophobic methyl (CH3) group which was substituted by 
isoleucine (I66) comprising of a bulkier hydrophobic hydroxyl (OH) group. The E92Q 
substitution replaces the negatively charged carboxylate group (COO-) in glutamic acid (E92) 
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with a neutral and bulkier amine group in glutamine (Q92). The H114L substitution 
substitutes the planar hydrophilic aromatic group (C6H6) from the histidine (H114) with a 
bulkier hydrophobic group from leucine (L114). The F121Y mutation substitutes the planar 
hydrophilic group in phenylalanine (F121) with a hydrophilic aromatic group from tyrosine 
(Y121). The Q148R mutation substitutes (glutamine with arginine) the hydrophobic 
carboxylic amine (an acid) with three bulky nitrogens (hydrophilic). The N155H single point 
mutation replaces the amine and the carboxylic group from asparagine (N155) with a planar 
aromatic group in histidine (H155) and remains hydrophilic. R263K (neutral) substitutes the 
(arginine with lysine) three amines with a less bulky amine, and obtained a negative charge 
and a minor change in orientation. 
 
Figure 3.5: A three-dimensional docking model showing the amino acid substitutions of A) T66I, B) E92Q, C) 
F121Y, D) H114L, E) N155H, F) Q148R, and G) R263K. The orange colour represents the wild-type amino 
acid and the grey is the single point mutation. 
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The minimisation energy and the root mean square deviation (RMSD) from modelling of the 
IN single point substitutions using Accelrys Discovery Studio 3.5 are detailed in Table 3.6.  
The amino acid substitutions exhibited overall acceptable minimisation energies ranging from 
the highest -13.07 (R263K) to the lowest -178.16 (F121Y). The lower the minimisation 
energy, the more stable the amino acid and the higher the minimisation energy the less stable 
the single point mutation. The RMSD measures the differences between the WT amino acid 
and the mutant; and all obtained substitutions exhibited RMSD values below 0.3 Å. The 
higher the RMSD value the greater the difference.  
 
Table 3.6: A summary of minimisation energies and the RMSD value of the single point 
mutations in IN, as determined by Accelrys Discovery Studio 3.5 software.   
  Minimisation Energy RMSD (Å) 
T66I -51.66 0.209 
E92Q -99.03 0.101 
H114L -84.98 0.016 
F121Y -178.16 0.041 
Q148R -21.92 0.139 
N155H -57.13 0.055 
R263K -13.07 0.195 
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3.4. Multiple sequence alignment exhibiting relevant site-directed mutations  
Based on the Sanger and MiSeq sequencing results, seven mutations were targeted to 
evaluate their impact on HIV-1 subtype C WT IN activity. These included FV6T66I, FV6E92Q, 
FV6H114L, FV6F121Y, FV6Q148R, FV6N155H and FV6R263K. A pET-15b vector with a cloned full-
length FV6WT IN gene was used as a backbone to successfully generate the seven mutants by 
site-directed mutagenesis. Nucleotide sequence analysis and an amino acid sequence 
alignment of the FV6WT IN and mutants (FV6MT) confirmed that all the desired mutations had 
been correctly introduced into the FV6WT IN backbone (Figure 3.6).  
 
                                                                                           
                   *        20         *        40         *        60         *            
05ZAFV6 : -FLDGIDKAQEEHEKYHSNWRAMASEFNLPPIVAKEIVASCDKCQLKGEATHGQVDCSPGIWQLDCTHLEGKVIL :  74 
T66I    : M.................................................................I........ :  75 
E92Q    : M.......................................................................... :  75 
H114L   : M.......................................................................... :  75 
F121Y   : M.......................................................................... :  75 
Q148R   : M.......................................................................... :  75 
N155H   : M.......................................................................... :  75 
R263K   : M.......................................................................... :  75 
                                                                                            
                                                                                            
             80         *       100         *       120         *       140         *       
05ZAFV6 : VAVHVASGYIEAEVIPAETGQETAYYILKLAGRWPVKVIHTDNGSNFTSAAVKAACWWAGIQQEFGIPYNPQSQG : 149 
T66I    : ........................................................................... : 150 
E92Q    : .................Q......................................................... : 150 
H114L   : .......................................L................................... : 150 
F121Y   : ..............................................Y............................ : 150 
Q148R   : .........................................................................R. : 150 
N155H   : ........................................................................... : 150 
R263K   : ........................................................................... : 150 
                                                                                            
                                                                                            
                 160         *       180         *       200         *       220            
05ZAFV6 : VVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIHNFKRKGGIGGYSAGERIIDIIATDIQTKELQKQIIKIQNFR : 224 
T66I    : ........................................................................... : 225 
E92Q    : ........................................................................... : 225 
H114L   : ........................................................................... : 225 
F121Y   : ........................................................................... : 225 
Q148R   : ........................................................................... : 225 
N155H   : .....H..................................................................... : 225 
R263K   : ........................................................................... : 225 
                                                                                            
                                                                                  
              *       240         *       260         *       280         *       
05ZAFV6 : VYYRDSRDPIWKGPAKLLWKGEGAVVIQDNSDIKVVPRRKAKIIKDYGKQMAGADCVAGGQNED- : 288 
T66I    : ................................................................- : 289 
E92Q    : ................................................................- : 289 
H114L   : ................................................................- : 289 
F121Y   : ................................................................- : 289 
Q148R   : ................................................................- : 289 
N155H   : ................................................................- : 289 
R263K   : ......................................K.........................- : 289 
                                                                                  
 
Figure 3.6: Alignment of the predicted FV6WT integrase enzyme amino acid sequence with the FV6 mutants, 
indicating the introduced mutations in red, and the position highlighted in yellow. Dots indicate identity to the 
FV6WT sequence. 
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3.4. Western-blot analysis of purified WT and mutant integrase  
The FV6WT and FV6MT recombinant IN enzymes were successfully expressed in E.coli BL21 
(pLys) cells by IPTG induction on a large scale, and purified using nickel chelating column 
chromatography. The purified IN stock concentrations were determined using the NanoDrop 
as to:  FV6WT (600 µM), FV6N155H (114 µM), FV6T66I (109 µM), FV6Q148R (86 µM), 
FV6F121Y (101 µM), FV6R263K (78 µM), FV6H114L (117 µM) and FV6E92Q (156 µM). The 
recombinant IN proteins were confirmed using a Western-blot ELISA assay specific to the 
histadine tagged on al FV6WT and FV6MT IN enzymes (Figure 3.7).  
 
Figure 3.7: Western-blot analysis of a purified wild-type and mutant HIV-1 subtype C integrase enzymes (32 
KDa) with Western-blot markers: SuperSignal® Molecular Weight Protein Ladder (Thermo Scientific, USA).  
The Western-blot does not include the standardization of protein concentration loaded onto the gel, but all HIV-
1 IN concentrations were determined and input amounts were standardized for subsequent functional assays. 
 
3.5. HIV-1 subtype C mutant strand transfer capacity  
All purified FV6WT and FV6MT were tested for their ability to initiate HIV-1 IN ST reaction. 
Mutants containing single mutations at positions FV6N155H, FV6T66I, FV6Q148R, FV6F121Y, 
FV6R263K, FV6H114L and FV6E92Q exhibited 30.5%, 37.1%, 60.2%, 63.2%, 3.4%, 66.1% and 
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21.5% reduced ST capacity as compared to wild-type, respectively (Figure 3.8).   All mutants 
with an exception of FV6R263K exhibited significant reduction (p-value < 0.05) in ST activity.  
  
 
 
Figure 3.8: HIV-1 subtype C mutant ST capacity with respect to the WT IN subtype C enzyme, using a plate-
based ELISA assay.  – WT IN-C –WT IN HIV-1 subtype C; HIV-1 IN ST (%) Activity – HIV-1 IN ST percent 
activity. P-values were calculated using GraphPad QuickCalcs: t test calculator: 
http://graphpad.com/quickcalcs/ttest1.cfm?Format=SD 
 
3.6. HIV-1 subtype C FV6WT and FV6MT IN DNA binding capacity  
All purified FV6WT and FV6MT were tested for their donor-DNA binding ability required for 
HIV-1 IN ST reactions. Figure 3.9 shows the SPR sensograms exhibiting an increase in RU 
due to the increasing retroviral DNA concentrations following interactions between FV6WT 
and FV6MT.  
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Figure 3.9: HIV-1 subtype C mutant donor (d) DNA binding capacity with respect to the FV6 WT IN enzyme. 
The analyte (dDNA) concentrations used are shown in the key, and the analyte concentrations for the relevant 
FV6 IN mutants are delineated in section 2.9 of the text.  
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Overall, with the exception of FV6MT T66I, the overall affinity (KD) of each mutant was 
lower than the FV6WT (Table 3.7). FV6MT T66I and N155H have an increased association 
rate (ka) relative to WT (an order of magnitude higher). FV6MT N155H also exhibited the 
fastest dissociation rate (kd), an order of magnitude higher than the WT. The Rmax (<200) and 
χ2 (≤10% of Rmax) values included in the Table are an indication of the goodness-of-fit to the 
Langmuir 1:1 binding model.  
 
Table 3.7: The kinetics of donor DNA binding to the HIV-1 FV6 IN mutants with respect to 
the IN WT. 
IN ka (Ms-1) kd (s-1) KD (µM) Rmax χ2 
WT 8.82 x102 3.78x10-4 0.429 131.940 11.650 
T66I 5.50x103 5.44x10-4 0.099 16.340 2.800 
E92Q 4.21x102 5.39x10-4 1.280  102.400 9.480 
H114L 3.90x102 3.92x10-4 1.005 88.420 5.140 
F121Y 5.80x102 4.11x10-4 0.709 38.690 3.590 
Q148R 8.99x102 7.97x10-4 0.887 48.460 5.790 
N155H 1.63x103 2.09x10-3 1.282 123.090 8.260 
R263K 3.74x102 5.17x10-4 1.382 96.180 5.620 
KD: Donor DNA overall affinity for the IN enzyme  
ka: Rate at which donor DNA binds the IN enzyme 
kd: Rate at which donor DNA dissociated from the IN enzyme 
Rmax: maximum dDNA binding capacity on IN surface  
χ2: Chi2-value is the goodness-of-fit of the sensograms 
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CHAPTER 4: DISCUSSION  
 
 
 
The INSTI RAL has recently been approved for use in third line salvage therapy in South 
Africa. Although EVG and DTG are yet to be included as components in any of the current 
South African ARV treatment guidelines, they are likely to be considered as future 
components of salvage therapy. There is currently no published data on any South African 
patients failing a RAL-containing regimen. Thus, to better understand the generation of ARV 
drug resistance against INSTIs in treatment-naïve and treatment-experienced HIV-1 subtype 
C infected South African patients, we conducted in vitro selection studies using RAL, EVG 
or DTG against a panel of WT and ARV drug resistant primary virus isolates. ARV drug 
resistant primary viruses harbouring combinations of the NRTI and/or NNRTI mutations 
M184V, K103N and K238N (Table 2.1) were specifically included in this study to explore 
their impact on the emergence of INSTI mutations, and enzyme fitness. Several groups have 
already shown that the interactions between RT and IN drug resistant mutations are important 
for the development of resistance and viral fitness (Buzon et al, 2009; Gupta et al, 2009; Hu 
and Kuritzkes, 2014). 
 
Baseline IN sequences of the six selected virus isolates confirmed the absence of any primary 
INI resistance mutations, and the presence of various combinations of subtype C signature 
polymorphic mutations (Table 3.1; positions 25, 31, 50, 72, 100, 101, 112, 124, 125, 136, 
201, 218, 234, 265, 269, 278 and 283; Rhee et al., 2008; Oliveira et al., 2012) in the different 
isolates. Overall, the impact of these naturally occurring polymorphisms on drug 
susceptibility remains unclear. In this study, some mutations were present in all six isolates 
(100%), for example, codons 101, 124 and 201. Polymorphic mutations at codons 101 and 
124 have been previously associated with DTG resistance (Garrido et al., 2011). Moreover, 
Marcelin et al., (2010) reported a significantly higher rate of T124A and L101I+T124A in 
patients failing RAL than in INI-naïve patients. In contrast, V201I did not appear to alter 
INSTI susceptibility (Da Silva et al., 2010; Ceccherini-Silbersteinet et al., 2010). 
Interestingly, I72V, which is associated with secondary drug resistance to INSTIs, was seen 
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in virus isolates FV6 and MR69 (Oliveira et al., 2012). Thus, it is possible that the presence 
of these natural polymorphic mutations in HIV-1 subtype C may or may not alter 
susceptibility to INSTIs.  
 
Natural polymorphisms at the sites of secondary mutations are common in non-B subtypes 
(Brenner et al., 2011; Fish et al., 2010; Garrido et al., 2010; Sierra et al., 2011). Of particular 
interest is the M50I polymorphism identified in MR89. M50I has been associated with drug 
resistance and IN enzyme impairment in combination with R263K in HIV-1 subtype B 
(Wares et al., 2012); and earlier reports identified M50I in 10-25% of INSTI-naïve patients 
infected with HIV-1 subtype B (Ceccherini-Silberstein et al., 2009). However, analysis of 
HIV-1 subtype C IN sequences in the Los Alamos database (www.hiv.lanl.gov; accessed 8 
June, 2015) showed that variation at this position is common, and its effect on INSTI 
susceptibility warrants further investigation.  
 
4.1. In vitro selection 
To better understand the possible generation of resistance against INIs we conducted in vitro 
selection studies using RAL, EVG and DTG using a dose-escalation method in PBMCs 
infected with ARV drug naïve- and RTI drug resistant HIV-1 subtype C primary viruses. 
Selection studies using dose-escalation have been successfully used to adapt viruses in the 
presence of RTIs and INIs (Vingerhoets et al., 2005; Kobayashi et al., 2011).  PBMCs were 
selected for use in the experiments since they most closely represent the natural infection 
setting. It should be noted that the choice in cell-line has also been observed to influence the 
development of resistance mutations during selection. For instance, selection with DTG in 
MT-2 cells has been associated with the development of substitutions T124A, S153F/Y and 
L101I in HIV-1 subtype B virus, and selection in cord blood monocytic cells (CBMCs) is 
associated with the emergence of the stochastic R263K mutation (Jones et al., 2007; Goethals 
et al., 2008; Shimura et al., 2008; Goethals et al., 2010; Quashie et al., 2012).  
 
Drug concentrations were progressively increased over a period of 184 days. Drug 
concentrations were kept constant to allow the virus to adapt, and virus break-through was 
associated with a reduction of levels of HIV-1 p24 in the supernatant, followed by a recovery 
period. Overall, there were differences in viral replication between the WT and RTI 
resistance viruses in the presence of the different INSTIs, likely attributed to the genetic 
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barriers to the emergence of mutations. Both the FV and MR isolates retained sufficient viral 
replication under RAL pressure, with identical drug pressure profiles until selection was 
terminated at P53 under RAL (266.24 nM, up to 38-133 fold higher than the IC50 2-7 nM) 
pressure (Figure 3.2). In contrast, the MR viruses grown under EVG and DTG pressure did 
not replicate at concentrations higher than 16.32 nM and 8.32 nM, respectively. Drug 
concentrations for the FV viruses could not be increased beyond 66.56nM for EVG and 32.64 
nM for DTG. Thus, MR and FV viruses could replicate at EVG and DTG concentrations that 
were 5.8-23.8 -fold higher than the IC50 (2.8 nM), and approximately 3.1-12.1 fold higher 
than the IC50 (2.7 nM), respectively. These results highlight that RAL pressure has a lower 
impact on viral replication than EVG and DTG in primary HIV-1 subtype C viruses. This 
could be attributed to the presence of the HIV-1 subtype C signature polymorphic mutations 
described above. Moreover, there is likely a fitness cost associated with pre-existing RTI 
resistance mutations in the MR viruses exposed to increasing concentrations of EVG and 
DTG. The RTI resistant mutant, M184V, is associated with loss (4-33%) in replication 
efficacy with respect to the WT HIV-1 (Wakefield et al., 1992; Back et al., 1996; Paredes et 
al., 2009), and K103N was reported to demonstrate a virus fitness cost of 4.7-7.9-fold with 
respect to WT (Cong et al., 2007) due to processivity defect in the RT enzyme (Back et al., 
1996). An alternative hypothesis is that the MR viral isolates were hypersusceptible to the 
INSTIs used in thus study, or their replication capacity/fitness could delay the onset of 
resistance to INSTIs. 
 
4.2. Drug resistance-associated mutations selected in vitro  
Overall, in vitro selection experiments with RAL, EVG and DTG resulted in the emergence 
of INSTI resistance mutations in some primary viruses, and Sanger-based and NexGen 
sequencing identified several mutations within the IN coding region, including the most 
common clinically significant INI-resistance mutations T66IK, E92Q, Q148RK, N155H, 
G118R, the rare F121Y as well as the nonpolymorphic mutation R263K that confers low-
level resistance to these drugs. INSTI resistance mutations were identified at P40-P53 for 
266.24 nM RAL, P39-P53/P21-P29 for 66.56 nM/16.32 nM EVG and P31-P53 for 66.56 nM 
DTG (Tables 3.2-3.5).  
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4.2.1. Resistance to RAL  
Population-based Sanger sequencing identified the emergence of the major primary mutations 
Q148R, N155H and N155H in FV6 (P44), MR69 (P39) and MR89 (P44), respectively.  Thus 
only two of the three (Q148H/K/R, N155H and the less common Y143H) signature pathways 
associated with RAL resistance were observed (Hazuda et al., 2007; Johnson et al., 2007). 
These results were verified using NexGen sequencing technology, where the major primary 
mutations were the predominant quasispecies. Additionally, the known secondary mutations 
associated with resistance to RAL, that is, L74M, T97A, E138K, G140S and G163R (Malet 
et al., 2008) were detected as minority quasipecies (≤5%) at various passages. Only 
quasispecies detected at proportions greater that 1% were reported. Next generation 
sequencing has not been used previously in detecting mutations during in vitro selection 
experiments. A higher degree of genetic variation and quasispecies was expected than from 
the Sanger-based sequencing, however, very few quasispecies were detected, with the 
majority of the populations detected being either WT or harbouring a major primary 
mutation. This is likely attributed to the selection process during passage in the PBMCs 
which enabled particular quasispecies to grow and predominate. Although several of these 
mutations were present during early passages, for example, the major accessory mutation 
E138K comprised 4% of the MR69 quasispecies detected at P24; it did not proliferate/expand 
in subsequent passages, implying a fitness cost. Of interest, MR69 resistance to RAL 
appeared to emerge using the Q148R pathway by P24 (Q148R was present at 96% and 
E138K was present at 4%). The emergence of E138K in combination with Q148R it is 
associated with >100-fold reduced RAL and EVG susceptibility (Underwood et al., 2012; 
Eron et al., 2013; Castagna et al., 2014). However, by P31 there were changes in resistance 
pathways to RAL with the emergence of N155H mutation. This is in contrast to previous 
reports where N155H mutant viruses emerged first and were subsequently replaced by 
Q148H (Canducci et al., 2009; Delelis et al., 2010). 
 
Resistance to RAL is known to confer cross- resistance to EVG. Q148R and N155H are non-
polymorphic mutations previously selected in vitro and in patients receiving RAL and EVG 
(Fransen et al., 2009; Garrido et al., 2012). Q148R alone is associated with reduced 
susceptibility (30 to 100-fold) to RAL and EVG (Goethals et al., 2008; Canducci et al., 2011; 
Kobayashi et al., 2011; Garrido et al., 2012; Abram et al., 2013), whilst N155H alone is 
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associated with reduced efficacy of RAL (~15-fold) and EVG (~30-fold) (Kobayashi et al., 
2011; Margot et al., 2012). The Q148H and N155H substitutions are associated with 
conformational changes within the catalytic pocket leading to an increase in the binding 
energy of INSTIs (Hare et al., 2010). The conformational changes observed are possibly due 
to the removal of the hydrophobic carboxylic amine in Q148 with the three nitrogen’s in 
R148 (Figure 3.5F); and the replacement of the carboxylic group and amine in N155 with the 
planar aromatic group in histidine (H155) shown in Figure 3.5E.  
 
Efficacy of RAL (and EVG) is further reduced when N155H occurs in combination with 
E92Q or other accessory INI-resistance mutations (Abram et al., 2013). M50I was detected at 
baseline in virus isolate MR89, and later N155H emerged resulting in a double mutant (Table 
3.1). Moreover, the M50I substitution has been associated with moderate resistance to DTG 
in combination with R263K, and without impact on enzyme fitness (Ceccherini-Silberstein et 
al., 2009; Quashie et al., 2012; Wares et al., 2014).   
 
Primary viruses FV3 and FV5 were able to efficiently replicate in the presence of 266.24nM 
RAL without the emergence of associated major primary mutations. It is possible that the 
baseline naturally occurring polymorphisms in these viruses contributed to their “natural 
resistance”, or alternatively other as yet unidentified changes may have contributed to this. 
Other mutations selected under RAL pressure were I161T and D41N in primary HIV-1 
subtype C isolates FV3 and FV5 respectively (data not shown). This has also been reported in 
other patient samples without known signature resistance mutations toward RAL. The D41N 
substitution is associated with a drug burden index score between 5 and 9 (Casadella et al., 
2014).  Although information regarding I161T is limited it is located within the C4 α-helix of 
the CCD (shown in Figure 3.4), thus conformational changes induced may affect drug 
binding and IN inhibition. 
 
As mentioned previously, several known secondary mutations associated with resistance to 
RAL (and EVG, DTG) were detected as minority quasipecies (≤5%) at various passages. 
During the selection experiments, they never emerged as predominant quasispecies, so their 
relevance in altering INSTI susceptibility could not be determined. For example, the E92V 
substitution which was detected in P16 in MR89 has only been selected in vitro using an 
experimental INI GS-9160, and was observed to increase resistance to RAL and EVG by 10 
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and 40-fold respectively (Jones et al, 2009). The Y143HS substitutions detected in FV3 
(P24), and MR89 (P17, P41) are extremely rare nonetheless were reported in patients on RAL 
treatment and are associated with a 5-10-fold resistance to RAL and minimal effects on EVG 
and DTG (Canducci et al., 2010; Delelis et al., 2010; Metifiot et al., 2010; Kobayashi et al., 
2011; Van Wesenbeeck et al., 2011; Garrido et al., 2012; Geretti et al., 2012; Abram et al., 
2013; Van der Borght et al., 2013). S147G observed in MR69 (P39, P44) and MR89 (P41) 
has been identified in patients receiving EVG treatment and is associated with 5-10-fold 
resistance to EVG, and negligible resistance to RAL (Shimura et al., 2008; Kobayashi et al., 
2011; Margot et al., 2012; Abram et al., 2013). Other mutations such as Q95K, Q146P, 
V151AL, S153FY and E157Q affect the fold resistance to RAL, EVG and DTG (Jones et al, 
2009; Kobayashi et al., 2011; Vavro et al 2013; Shimura et al., 2007; Fun et al., 2010). The 
S230R substitution is associated with negligible resistance to INIs (Goethals et al., 2008; 
Goethals et al., 2010; Blanco et al., 2011; Geretti et al., 2012).  
 
The pol from MR81 grown under RAL selection pressure could not be amplified despite 
adequate p24 antigen levels in the culture supernatant, hence the presence/absence of INSTI 
drug resistance mutations could not be verified. Different amplification primers could be 
designed for future work. Overall, three of the five primary HIV-1 subtype C isolates 
developed the common RAL resistance mutations, implying that HIV-1 subtype C infected 
South African patients receiving a RAL-containing regimen are likely to develop drug 
resistance using the Q148R and N155H pathways, as reported for subtype B. Understanding 
why the two WT primary viruses could effectively replicate in the presence of high 
concentrations of RAL warrants further investigation.    
  
4.2.2. Resistance to EVG 
Population-based Sanger and NexGen sequencing confirmed the emergence of the rare 
primary INI-resistance mutation F121Y in FV3, and the major primary mutations T66I, T66I 
and T66K in FV6, MR69 and MR81, respectively, following selection with EVG in primary 
HIV-1 subtype C virus isolates. No Sanger data was obtained for MR89, but NexGen data 
confirmed the presence of T66I. F121Y, T66I and T66I/R263K have been reported before in 
HIV-1 subtype B, selected under INSTI pressure in a MT-2 cell line (Margot et al., 2012) and 
under RAL (both in vitro and in patients) and EVG (Rowley, 2008; Shimura et al., 2008). 
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Additionally, the major accessory mutation R263K was detected in combination with T66I in 
FV6, and D232N and A179G (data not shown) was detected in FV3 and FV5, respectively. 
NexGen sequencing also identified the presence of Q148K in FV5 at 31% of the quasispecies 
at P27. This percentage falls within the cut-off limit of detection for Sanger sequencing, so 
may have not been recorded. Q148R constituted 60% of the quasispecies of MR81 at P27, 
but this coincided with the emergence of N155H (13%) and T66K (7%), following which 
T66K then became the predominant quasispecies. It is likely that these mutations are separate 
pathways to EVG resistance, with T66K being more favourable to optimal MR81 replication.   
 
This is the first report of selection of the rare polymorphic mutation F121Y in primary HIV-1 
subtype C viruses from South Africa. F121Y is associated with high-level resistance (>5-
fold) to RAL, and is associated with over 10-fold resistance to EVG (Shimura et al., 2007; 
Kobayashi et al., 2008; Geretti et al., 2012). F121Y exhibits >100-fold resistance in 
combination with known secondary resistance mutations, but does not appear to affect DTG 
efficacy (Kobayashi et al., 2008; Margot et al., 2012). This mutation is associated with the 
replacement of the planar hydrophilic group with a hydrophilic aromatic group during F121Y 
substitution (Figure 3.5C). Interestingly, the D232N substitution is considered a secondary 
mutation associated with RAL resistance (Malet et al., 2009; Loizidou et al., 2009); therefore 
it could be speculated that the combination of F121Y/D232N observed in FV3 may affect 
drug resistance, enzyme fitness and in vitro retroviral DNA binding. EVG was also observed 
to induce drug resistance-associated mutation A179G in FV5 located within the C3 α-helix of 
the catalytic core domain essential for DNA binding (Figure 3.4). However, the biochemical 
impact of substitution A179G on IN function, enzyme fitness and DNA binding is yet to be 
established.  
 
T66I has been selected both in culture and in patients on EVG treatment (Shimura et al., 
2008; Goethals et al., 2008; Kobayashi et al., 2008; McColl and Chen, 2010; Molina et al., 
2012; Margot et al., 2012), whilst the R263K was identified through in vitro selection with 
EVG and DTG and again isolated from patients on separate RAL and DTG treatment (Blanco 
et al., 2011; Margot et al., 2012; Quashie et al., 2012; Cahn et al., 2013; Mesplède et al., 
2013). McColl and Chen, 2010 reported T66I in combination with accessory mutations 
R263K, F121 and S153Y in non-subtype C HIV. T66I is associated with reduced efficacy to 
EVG by approximately 15-fold (Kobayashi et al., 2011; Margot et al., 2012) but does not 
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affect the efficacy of RAL (Kobayashi et al., 2011; Margot et al., 2012; Van der Borght et 
al., 2013) or DTG (Abram et al., 2013). The R263K substitution is associated with 2-fold 
(RAL and EVG) and 3-5-fold (DTG) reduced efficacy (Margot et al., 2012; Garrido et al., 
2012; Quashie et al., 2012; Cahn et al., 2013; Mesplède et al., 2013).  
 
As with RAL pressure, selection with EVG induced a greater variety of mutations at low 
proportions (<20%) such as the major primary mutations E92V (FV6), Y143KRS (MR81), 
Q148HKR (all six isolates), N155HS (FV6, MR81); major accessory mutations T97A (FV5, 
FV6, MR81, MR89), G140S (FV5, FV6), V151L (MR81, MR89), S153SY (FV3, FV6, 
MR81, MR89), G163KR (FV5, FV6, MR81, MR89), S230R (FV6), R263K (FV6, MR89); 
rare primary INI-resistance mutations G118R (FV5), P145S (MR69), E157Q (FV6, MR81); 
and miscellaneous INI-associated mutations Q95K (FV6, MR81, MR89). Because none of 
these mutations ultimately emerged as predominant quasispecies, their contribution to EVG 
resistance is unknown.  
 
The impact of some of these mutations were discussed above with an exception of T66A, 
E92GQ, G118R, G140CS, Q148HK and N155T. The T66A mutation was previously 
reported in patients receiving EVG treatment and was established to have approximately 10-
fold EVG resistance (Hatano et al., 2010; Winters et al., 2012; Molina et al., 2012; 
Kobayashi et al., 2011; Margot et al., 2012; Abram et al., 2013; Van der Borght et al., 2013). 
The E92GQ mutations have been selected in patients and in vitro under EVG pressure and 
are associated with respective 10-fold resistance and 30-fold resistance to EVG (Van 
Wesenbeeck et al., 2011; Margot et al., 2012; Abram et al., 2013). Interestingly, the G118R 
substitution has only been selected using RAL (in vivo) and using DTG (in vitro), and is 
associated with increased resistance to RAL (10-fold) and EVG/DTG (3-fold) (Kobayashi et 
al., 2008; Malet et al., 2011; Geretti et al., 2012; Quashie et al., 2012; Quashie et al 2013). 
The G140CS substitutions are associated with over 100-fold increased resistance towards 
RAL and EVG and up to 10-fold resistance towards DTG, only in combination with INI 
resistant mutations at position Q148. These nonpolymorphic mutations (G140CS) have been 
selected in patients receiving RAL/EVG treatment (Hatano et al., 2010; Blanco et al., 2011; 
Winters et al., 2012; Fransen et al., 2012; Garrido et al., 2012; Hurt et al., 2014). The 
substitutions Q148HK are associated with increased resistance of 5-fold and 10-fold towards 
RAL and EVG respectively, and have been selected both in vitro and in patients receiving 
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RAL and EVG treatment. The N155ST substitution has been identified following selection 
with experimental agents and was observed to increase resistance to RAL and EVG (Jones et 
al, 2009; Kobayashi et al., 2011; Van der Borght et al., 2013). 
 
Overall, all the primary HIV-1 subtype C isolates developed EVG resistance mutations, 
implying that HIV-1 subtype C infected South African patients receiving an EVG-containing 
regimen in future are likely to easily develop drug resistance using the T66IK pathway, as 
reported for subtype B (assuming they do not have any RAL-associated mutations from 
failing a RAL-containing regimen). T66IK emerged early, implying a low genetic barrier to 
development of drug resistance, whereas Q148K emerged more slowly. The emergence of 
F121Y is reported to be rare for subtype B, but may be a more common pathway for HIV-1 
subtype C. Thus, future work should focus on investigating this further.     
 
4.2.3. Resistance to DTG 
Population-based Sanger sequencing revealed that in vitro selection with DTG induced a non-
polymorphic mutation E92Q in FV3 (P44). NexGen sequencing data for FV3 P44 could not 
be obtained due to limited sample volumes. The E92Q has been isolated previously in 
patients receiving RAL (Blanco et al., 2011; Molina et al., 2012) and EVG (DeJesus et al., 
2012; Winters et al., 2012) treatment; and following in vitro selection with RAL (Kobayashi 
et al., 2011). This serves as the first report of in vitro selection of E92Q using primary HIV-1 
subtype C in a PBMC-culture. The E92Q has been described as the primary EVG-resistance 
mutation associated with virological failure in non-subtype C viruses (Molina et al., 2012; 
White et al., 2013). The E92Q substitution has been shown to decrease susceptibility to RAL 
(5-10-fold), EVG (~30-fold) and DTG (~1.5-fold) (Shimura et al., 2008; Jones et al., 2009; 
Kobayashi et al., 2011; Van Wesenbeeck et al., 2011; Abram et al., 2013). As shown in 
Figure 3.5B E92Q substitution is associated with a change in charge due to the replacement 
of the negatively charged carboxylate group (COO-) with a neutral amine (bulky) group in 
Q92, therefore resulting in INSTI resistance. 
 
Selection with DTG induced the same mutations at low proportions (<20%) as described 
above; namely, T66A, Y143R and N155S, the rare F121Y and a miscellaneous INI-
associated mutation E157Q substitution. Similarly, because quasispecies harbouring these 
mutations never became the predominant quasispecies, the impact of these mutations remains 
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unclear. The T66A was previously selected in vitro using DTG, but is associated with 
negligible DTG resistance (Van Wesenbeeck et al., 2011; Abram et al., 2013). There are no 
reports of selection of Y143R using DTG and the substitution is not associated with reduced 
potency of DTG similar to N155S and F121Y (Kobayashi et al., 2011; Van Wesenbeeck et 
al., 2011; Margot et al., 2012; Abram et al., 2013; Van der Borght et al., 2013) selected in 
this study. The E157Q mutation has no known effects on DTG susceptibility, and its selection 
using DTG is yet to be reported. However, of the major accessory mutations only L74M, 
E138K, S153Y and R263K (Table 3.5) have been selected before in vitro and in patients. 
L74M and E138K single mutations are not associated with increased resistance towards 
DTG. Resistance was only observed when L74M and E138K were in combination with 
primary INI resistance mutations. Nonetheless, S153Y and R263K are known to induce 2-
fold resistance towards DTG (Quashie et al., 2012; Underwood et al., 2012; Cahn et al., 
2013; Eron et al., 2013; Vavro et al., 2013; Castagna et al., 2014). Although, the G140A and 
V151IL substitutions have only been observed in this study through selection with DTG; they 
are associated with a 10-fold and 3.6-fold resistance towards DTG (Brenner et al., 2011; 
Garrido et al., 2011; Kobayashi et al., 2011; Underwood et al., 2012). 
 
Overall, our results support existing data and confirmed that the genetic barrier to the 
development of drug resistance to the second generation INSTI, DTG was higher than RAL 
or EVG (reviewed by Wainberg and Han Y-S, 2015). This implies that HIV-1 subtype C 
infected South African patients receiving a DTG-containing regimen in future are unlikely to 
experience virological failure easily. 
 
4.3. Genetic drug resistance barrier and cross resistance  
Genetic drug resistance barrier is defined as the accumulative number of drug resistance-
associated mutations required by a virus to escape drug-selective pressure (Maiga et al., 
2009; Van de Vijver et al., 2006) and is an essential aspect that contributes to the emergence 
of drug resistant isolates.  A comparison in genetic drug resistance barriers between HIV-1 
subtypes was evaluated following selection with RAL and EVG (Piralla et al., 2011). The 
occurrence of single point mutations during selection with RAL (Q148R and N155H) and 
EVG (T66I and F121Y) known to confer high-level resistance (Malet et al., 2008; Garrido et 
al., 2008) was a demonstration that HIV-1 subtype C shares a modest genetic resistance 
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barrier with non-subtype C isolates. As described above, our results confirm that WT and RTI 
drug resistant HIV-1 subtype C primary viruses have a modest genetic resistance barrier to 
RAL and EVG. Moreover, the two drugs share extensive cross resistance. For instance, the 
RAL signature mutations (N155H and Q148R) which emerged in FV6, MR69 and MR89 
would render these viruses resistant to EVG. The only RAL-associated mutations yet to be 
selected by EVG are Y143C/R/H, which have been observed to remain susceptible to EVG 
(Métifiot et al., 2011). Similarly, the selection of primary mutations (T66IK, F121Y and 
Q148K) by all six virus isolates using EVG suggests substantial cross resistance with RAL 
which was previously established (McColl et al., 2007; Van Baelen et al., 2008; Ceccherini-
Silberstein et al., 2009). However, DTG demonstrated little to no cross resistance with RAL 
since it was shown to exhibit considerable antiviral activity towards isolates containing RAL 
and EVG resistance mutations (Sato et al., 2010; Kobayashi et al., 2011). The selection of 
E92Q could lead to increased resistance toward DTG. Therefore, it is essential that genetic 
variability within the HIV-1 subtype C is monitored, even though no considerable cross 
resistance was observed between DTG and the first generation INSTIs RAL and EVG. 
  
4.4. HIV-1 IN strand transfer efficacy 
It is well established that all major INI resistance mutations are associated with reduced 
subtype B IN activity and viral replication capacity (Hu and Kuritzkes, 2010). All the 
recombinant HIV-1 subtype C mutants used in this study exhibited varying degrees of loss of 
enzyme fitness with respect to the WT IN enzyme (Figure 3.8). Single mutant enzymes 
consisting of FV6Q148R, FV6F121Y and FV6H114L displayed a substantial loss (60.2%, 63.2% 
and 66.1%, respectively) in ST capacity.  
 
Results for the ST capacity of the FV6Q148R mutant correlate with findings from Abram et al., 
(2013), who showed an approximately 62% reductions in ST capacity for the HIV-1 subtype 
B LAI/IIB IN. This implies that the impact of the Q148R substitution on HIV-1 subtypes B 
and C ST capacity is similar. Interestingly, a substantial loss (>90%) in ST activity due to the 
Q148R substitution was reported for HIV-2 group B IN using in vitro gel-based enzymatic 
activity assays (Ni et al., 2011). Little data exists on the rare F121Y IN mutant ST capacity. 
Marinello et al., (2008) showed that among the HIV-1 subtype B HXB2 IN mutants tested 
(Q148K/R, T66I, F121Y, N155H and E92Q), F121Y demonstrated the highest reduction in 
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ST capacity comparable to the ~25% to ~50% ST activity reported using a dual ST/3’-P gel-
based assay. This is comparable to our data (36.8% ST activity). Interestingly, only the single 
mutation H114Y, and not the FV6H114L (Table 3.2) has been reported by Goethals et al., 
(2008) with observations of negligible reduction in subtype B virus RC. This is the first 
report showing a substantial loss in IN ST efficiency due to the H114L substitution in IN as a 
result of RAL pressure.  
 
The N155H exhibited a 30.5% reduction in ST activity which is within the reported range of 
40% to ~75% reported previously in subtype B IN (Marinello et al., 2008; Metifiot et al., 
2011; Abram et al., 2013). The R263K substitution alone is associated with impaired (by 
>50%) ST activity in subtype B IN across the range of protein concentrations tested (23-1440 
nM; Mesplède et al., 2013) in contrast to the insignificant loss (3.4%) in ST efficiency of 
FV6R263K observed at IN concentrations of 200 nM using a similar plate-based IN assay.  
 
Varying results have been reported in the literature for the ST capacity for T66I and E92Q IN 
mutants. ST capacities of mutant INs T66I and E92Q have been reported at approximately 
20% and 50% in subtype B IN, respectively (Marinello et al., 2008). This is different from 
our findings, where FV6T66I and FV6E92Q exhibited 62.9% and 78.8% ST activity, 
respectively. Additional studies show more differential patterns. For example, in Malet et al 
(2008) the E92Q mutant demonstrated only a 12% ST activity in a gel-based IN subtype B 
ST reaction, whereas T66I has also been reported to exhibit 88%-103% ST activity in 
subtype B IN (Fikkert et al., 2003). Abram et al., (2013) reported approximately 40% and 
70% for T66I and E92Q mutants, respectively.  
 
Overall, the ST capacity of some HIV-1 subtype C mutants are different from subtype B, and 
warrant further investigation to evaluate their impact (and the impact of double mutants) on 
RC and virological failure in IN-treated patients in South Africa.  
  
4.5. HIV-1 IN DNA binding kinetics 
SPR was used for the first time in this study to investigate the affinity of the selected IN 
mutants on retroviral dDNA binding with respect to the FV6WT IN enzyme, a step which is 
essential for the HIV-1 IN ST reaction.  
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Previous work looking at the kinetics of strands transfer is limited, and is based on 
determining kinetics using a scintillation proximity assay (Dicker et al., 2008), and IN-DNA 
binding on a microplate based assay (Quashie  et al., 2012). Dicker et al., (2008) conducted 
biochemical analyses on the HIV-1 subtype B NL4-3 WT and eight MT (T66I, V75I, E92Q, 
Q148R, N155H, T66I/E92Q, T66I/N155H and V75I/M154I) enzymes. Overall, they showed 
lower affinity binding of the INSTI to the integrase complex, as a result of faster dissociation 
rates. Moreover, Q148R was the most defective enzyme. Although different methodologies 
were used, our results showed that only FV6N155H exhibited a faster dissociation rate 
compared to the FV6WT IN. The overall affinity of the donor DNA for IN (KD) was 4.36 fold 
higher in the T66I mutant, attributed to the increased association rates compared to the 
FV6WT IN, whereas all other IN mutants exhibited 2.99, 2.34, 1.65, 2.07, 2.99 and 3.23 fold 
lower overall affinities for donor DNA of INE92Q, INH114L, INF121Y INQ148R, INN155H and 
INR263K, respectively.  
 
The fold increases/decreases of overall DNA binding affinities of the IN variants does not 
parallel the ST data (as presented in Figure 3.8 and discussed in section 4.3 above). For 
example, despite the 3.23 fold lower overall affinity of DNA binding to the INR263K, the 
enzyme is still capable of performing the ST step with 96.6% efficiency. The structure of the 
full length HIV-1 IN remains unresolved, but Hare et al., (2010ab) has reported a full length 
crystal structure of a related prototype foamy virus (PFV) IN (Hare et al., 2010a) and 
cocrystal structures of the PFV intasome with RAL and EVG (Hare et al., 2010b) . The PFV 
IN serves as a reliable surrogate for structural analyses due to active-site similarities (Abram 
et al., 2013).  Hare et al., (2012) showed that the main chain amides of the PFV IN involved 
in DNA contact were Tyr212 and Gln186, which structurally correspond to HIV-1 Tyr143 
and Asn117, respectively (Hare et al., 2010b). In the PFV structure, the Tyr212 is located 
directly next to the drug binding pocket and the PFV side chain of Tyr212 (analogous to 
HIV-1 Tyr143) makes π-π stacking interactions with bound RAL; these interactions are very 
likely substantial contributors to inhibitor binding in the PFV IN. Furthermore, due to the 
similarity in the structure and function of the PFV and HIV-1 integrase enzymes, it is 
possible to draw conclusions on the manner in which mutations at position Tyr143 of HIV-1 
IN can impact on drug efficacy (Hare et al., 2012). However, mutations affecting drug 
efficacy may not necessarily affect DNA binding, just as direct INSTI and amino acid residue 
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interaction is not required for drug resistance. For example, PFV IN residues Ser217 and 
Asn224, corresponding to HIV-1 IN Gln148 and Asn155 respectively, do not directly contact 
bound INSTIs in the cocrystal structures, leaving the molecular basis of resistance for these 
major pathways open to further research (Hare et al., 2012). Moreover, substitutions at 
positions Ser217 (analogous to HIV-1 Q148) and Asn224 (analogous to HIV-1 N155) were 
observed to hinder metal coordination by only binding a single metal atom, due to subtle 
conformational changes within the active site (Hare et al., 2010).  
 
4.6. Overall impact of mutations on structure and function 
HIV-1 IN is comprised of an N-terminal zinc finger domain, a C-terminal domain vital for 
DNA binding and both flank the central catalytic core domain (CCD), key for catalytic 
activity (Engelman et al., 1991; Dyda et al., 1994). The T66I, E92Q, H114L Q148R and 
N155H substitutions border the catalytic pocket (Figure 3.4) in proximity to the catalytic 
DDE triad (D116, D64 and E152) (Hare et al., 2010a). The T66 amino acid borders the active 
site, whilst two of the DDE triad residues (D64 and E152) surround N155, the E92 residue is 
surrounded by DDE triad residues (D64 and D116), whilst all three catalytic DDE triad 
(D116, D64 and E152) residues are in close proximity to the Q148 residue. Since the Q148 
residue lies within the catalytic β4-α2 loop, Q148RHK substitutions would change the 
flexibility of this loop, and could result in reduced efficiency of D64 and E152 metal ion 
binding (Dicker et al., 2007), impede retroviral DNA 5’-end binding (Johnson et al., 2006), 
and induce decreased  hydrogen-bond interactions between Q148 and E152 (Hare et al., 
2011). The T66 residue is located within the β2 sheet distal from the catalytic DDE triad in 
close proximity to the viral DNA 3’-end and the N155 residue. Substitutions at this T66 
position are associated with reduced viral DNA binding due to altered interactions with the 
retroviral DNA 3’-end. The T66 substitution also alters metal ion coordination due to its 
effects on residue N155 primarily associated with metal cofactor binding (Goethals et al., 
2008; Hare et al., 2010b; Hightower et al., 2011). The N155 residue is located within the α4-
helix and orientates directly into the active site. The H155 substitution forms hydrogen bonds 
with the key metal ion binding residue D116, which is associated with altered metal binding 
and reduced ST efficiency (Hazuda et al., 2004). Moreover, substitutions of residue N155 
alter the salt bridge with the phosphate of the terminal 3’-adenosine resulting in a widened 
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base of the catalytic pocket, and similarly alter metal ion coordination within the catalytic 
triad (at residue E152) (Hare et al., 2010b; Hightower et al., 2011).  
 
The E92 residue is positioned within a β3-α1 loop in close proximity with the active site. The 
E92Q substitution is associated with a loss of the negative charge, which makes metal ion 
coordination and hydrogen bonding with water molecules less favourable (Goethals et al., 
2008). The R263 residue is positioned within the C-terminal domain essential for DNA 
binding. The R263K substitution is associated with a loss of three hydrophilic amines, neutral 
in charge, replaced by one negatively charged amine and a change in amino acid orientation. 
Overall, these INSTI resistance mutations introduce subtle modifications in the local IN 
secondary structure, which results in altered metal ion coordination and changes in the 
interactions with retroviral DNA.  
 
Amino acid substitutions will impact on IN stability, which results from changes in the 
degree of hydrophilicity, hydrophobicity, charge and size. For instance, T66I and H114L 
were shown to gain hydrophobic side chains, whereas F121Y (positioned on the opposite side 
of the active site on the α-helix) and Q148R were shown to gain hydrophilic side chains 
(Figure 3.5B, D and Figure 3.5C, F). The fragment encompassing amino acid residues 140-
149 (the flexible loop (G140-G149)) is associated with low diffraction, and is therefore 
consistently not well resolved (Chiu and Davies, 2004; Jaskolski et al., 2009). The two 
glycines (G140 and G149) act at each end as hinges; due to their small side chain size they 
allow a high degree of rotation of the poly-peptide backbone. Greenwald et al., (1999) 
demonstrated conformational restriction by substitution of the two glycine molecules with 
alanine leading to complete resolution and minimized flexibility (Greenwald et al., 1999). 
Esposito and Craigie (1998) demonstrated a loss in 3’-P and ST activities due to substitutions 
Q148HKR, attributed to the loss in interaction efficiency with the tip of viral DNA LTR, as 
well as chemical cross linking between the IN residue at position 148 and the 5’-C on the 
overhang of the viral DNA lower strand. The bulkier side chains of the acquired amino acids 
were also reported to alter viral DNA binding, thereby inhibiting both IN 3’-P and ST 
reactions (Métifiot et al., 2010b). Overall, the mutated amino acids are associated with 
subsequent changes in IN function and overall structure, as defined by their side chains.  
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4.7. Concluding remarks  
HIV-1 subtype C primary virus isolates were selected in vitro in primary PBMCs under INI 
pressure and found to select for the described major IN mutations, similar to what has been 
reported from patient clinical samples worldwide. Although most of the mutations identified 
herein have been described before, this study serves as the first description of resistance 
mutations and one H114L selected in HIV-1 subtype C within the South African context. 
Mutations selected with RAL (Q148R and N155H) and EVG (T66IK) served as a 
confirmation of cross resistance between both drugs in HIV-1 subtype C comparable to 
subtype B, as reported in western countries where the drugs first become available. 
Interestingly, DTG selected for negligible levels of substitutions at positions (associated with 
resistance to RAL and EVG) T66, Y143, Q148 and N155. However, these mutants remained 
inhibited as minor quasispecies, and likely did not expand due to drug pressure. This led to 
the supposition that, while cross resistance (to RAL and EVG) mutations were selected by 
DTG, for these mutations to gain prevalence within HIV-1 subtype C quasispecies and induce 
resistance towards DTG, requires accumulation of a combination of substitutions at 
resistance-associated (or potentially unknown) positions.  
 
This study serves as the first to report on the impact of HIV-1 subtype C integrase mutations 
on ST activity within the South African context, and the first time that SPR has been utilized 
as a technique to describe the DNA binding affinities to IN. All resistance mutations selected 
were confirmed to induce loss in ST efficiency, and the biochemical (losses in ST efficiency) 
patterns proved significant (with the exception of R263K) and dissimilar to non-subtype C IN 
ST patterns reported previously. The loss in ST efficiency can be associated to FV6MT DNA 
binding and this can only be confirmed to be one of many contributing factors (i.e. metal ion 
coordination, effects of mutations on IN local secondary structure), especially with 
substitutions that were determined to be in close proximity to the active site. 
 
4.8. Ongoing/future work 
This study forms the basis for continued research into the relevance of naturally occurring 
polymorphisms as well as the known major (and rare) primary and accessory mutations in 
HIV-1 subtype C IN, in order to better inform patient responses and outcomes on INSTI-
containing regimens. 
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Because we experienced great difficulty in expanding the mutated primary viruses in PBMCs 
for growth competition assays to compare relative viral fitness of WT and mutant viruses, 
future work should focus on cloning the IN mutants into a backbone to generate replication 
competent virus to be used in these assays. Phenotypic inhibition assays in the presence of 
each INSTI could then give an accurate indication of the fold differences in drug 
susceptibility. Site-directed mutagenesis can be used to further evaluate the impact of all the 
detected naturally occurring polymorphisms on enzyme activity. Additionally, SPR 
experiments can be repeated in the presence of each inhibitor to provide more insights into 
enzyme functions.  
 
As RAL use in the South African public sector increases, it is expected that patients with 
virological failure will develop drug resistance mutations to RAL. Emerging data on the 
mutation patterns will be used to generate additional mutants and evaluate their impact on the 
biological functioning of the enzyme.  
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